<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>entb0129form10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>United States Securities and Exchange
Commission</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>Washington, D.C.&nbsp;&nbsp;20549</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 14pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>Form 10-K</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; padding-right: 1.6pt; font: 11pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9745;</FONT></TD>
    <TD STYLE="width: 89%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 1.6pt 0pt 0">ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE
        SECURITIES EXCHANGE ACT OF 1934:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0.8pt 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 1.6pt 0pt 0">For the fiscal year ending August 31, 2012</P></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 11%; padding-right: 1.6pt; font: 11pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="width: 89%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 1.6pt 0pt 0">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF
        THE SECURITIES EXCHANGE ACT OF 1934:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0.8pt 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 1.6pt 0pt 0">For the transition period from ___________ to ___________.</P></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">Commission file number: 333-154989</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>ENTEST BIOMEDICAL, INC.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">(Name of small business issuer in its
charter)</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 42%; padding-right: 1.6pt; font: bold 11pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 13%; padding-right: 0.8pt; font: 11pt/115% Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 45%; padding-right: 1.6pt; font: bold 11pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>26-3431263</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of incorporation or organization)</FONT></TD>
    <TD STYLE="font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><B>4700 Spring Street, Suite 304, La
Mesa, California, 91942</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">(Address of Principal executive offices)</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">Issuer&rsquo;s telephone number: ( <B>619)
702-1404</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">_______________</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Securities registered under Section 12(b) of the &ldquo;Exchange
Act&rdquo; None</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Securities registered under Section 12(g) of the Exchange
Act: None</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes &nbsp;&#9744;&nbsp;&nbsp;&nbsp;No &#9745;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of Regulation S-K (&sect; 229.405 of this chapter) is not contained herein, and will not be contained, to
the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of
this Form 10-K or any amendment to this Form 10-K</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 5.6pt; line-height: 115%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt; line-height: 115%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 24%; padding-right: 1.6pt; line-height: 115%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Large accelerated filer &#9744;</FONT></TD>
    <TD STYLE="width: 20%; padding-right: 1.6pt; line-height: 115%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accelerated filer &#9744;</FONT></TD>
    <TD STYLE="width: 56%; padding-right: 1.6pt; line-height: 115%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non accelerated filer &#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding-right: 1.6pt; line-height: 115%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Smaller reporting Company &#9745;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%; text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Indicate by check mark whether the registrant is a shell
company (as defined in Rule 12b-2 of the Act).&nbsp;&nbsp;Yes &#9744;&nbsp;&nbsp;&nbsp;No &#9745;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Indicate by check mark
whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9745;</FONT></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">State the aggregate market value of the voting and non-voting
common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average
bid and asked price of such common equity, as of the last business day of the registrant&rsquo;s most recently completed second
fiscal quarter:&nbsp;$528,715</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of January 25, 2013
Entest BioMedical, Inc. had 446,519,900 common shares outstanding, 3,201,397 Series B Preferred shares outstanding, and
5,000 Series AA preferred shares outstanding and 75,000 Non Voting Convertible Preferred shares outstanding.</P>

<P STYLE="font: 12pt/1.5pt Times New Roman, Times, Serif; margin: 8.5pt 0 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 0pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: justify">In this annual report, the terms &ldquo;Entest
BioMedical, Inc.. &rdquo;, &ldquo;Entest&rdquo;,&nbsp;&nbsp;&ldquo;Company&rdquo;, &ldquo;we&rdquo;, or &ldquo;our&rdquo;, unless
the context otherwise requires, mean Entest BioMedical, Inc., a Nevada corporation, and its subsidiary.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">This annual report on Form 10-K and
other reports that we file with the SEC contain statements that are considered forward-looking statements.&nbsp;&nbsp;Forward-looking
statements give the Company&rsquo;s current expectations, plans, objectives, assumptions or forecasts of future events. All statements
other than statements of current or historical fact contained in this annual report, including statements regarding the Company&rsquo;s
future financial position, business strategy, budgets, projected costs and plans and objectives of management for future operations,
are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &ldquo;anticipate,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo; &ldquo;projects,&rdquo; &ldquo;ongoing,&rdquo; &ldquo;expects,&rdquo;
&ldquo;management believes,&rdquo; &ldquo;we believe,&rdquo; &ldquo;we intend,&rdquo; and similar expressions. These statements
are based on the Company&rsquo;s current plans and are subject to risks and uncertainties, and as such the Company&rsquo;s actual
future activities and results of operations may be materially different from those set forth in the forward looking statements.
Any or all of the forward-looking statements in this annual report may turn out to be inaccurate and as such, you should not place
undue reliance on these forward-looking statements.&nbsp;&nbsp;The Company has based these forward-looking statements largely on
its current expectations and projections about future events and financial trends that it believes may affect its financial condition,
results of operations, business strategy and financial needs. The forward-looking statements can be affected by inaccurate assumptions
or by known or unknown risks, uncertainties and assumptions due to a number of factors, including:</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 11pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 13%; padding-right: 1.6pt; text-align: right; line-height: 115%; font-family: Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 87%; padding-right: 1.6pt; line-height: 115%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp; dependence on key personnel;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%; font-family: Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD>
    <TD STYLE="padding-right: 1.6pt; line-height: 115%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp; competitive factors;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%; font-family: Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD>
    <TD STYLE="padding-right: 1.6pt; line-height: 115%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp; degree of success of research and development programs</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%; font-family: Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD>
    <TD STYLE="padding-right: 1.6pt; line-height: 115%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp; the operation of our business; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%; font-family: Calibri, Helvetica, Sans-Serif"><FONT STYLE="font: 10pt Symbol">&#183;</FONT></TD>
    <TD STYLE="padding-right: 1.6pt; line-height: 115%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp; general economic conditions</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">These forward-looking statements speak
only as of the date on which they are made, and except to the extent required by federal securities laws, we undertake no obligation
to update any forward-looking statements to reflect events or circumstances after the date on which the statement is made or to
reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the
extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any
forward-looking statements. All subsequent written and oral forward-looking statements attributable to the Company or persons acting
on its behalf are expressly qualified in their entirety by the cautionary statements contained in this annual report.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 0pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>PART I</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Item 1. Business</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">We were incorporated in the
State of Nevada on September 24, 2008 as JB Clothing Corporation. &nbsp;Until July 10, 2009, our principal business objective was
the offering of active/leisure fashion design clothing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On July 10, 2009 we abandoned
our efforts in the field of active/leisure fashion design clothing when we acquired 100% of the share capital of Entest BioMedical,
Inc., a California corporation, (&ldquo;Entest CA&rdquo;) from Bio-Matrix Scientific Group, Inc. (&ldquo;BMSN&rdquo;) for consideration
consisting of 10,000,000 shares of the common stock of the Company and the cancellation of 10,000,000 shares of the Company owned
and held by Mr. Rick Plote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">As a result of this transaction,
the former stockholder of Entest CA held approximately 70% of the voting capital stock of the Company immediately after the transaction.
&nbsp;For financial accounting purposes, this acquisition was a reverse acquisition of the Company by Entest CA under the purchase
method of accounting, and was treated as a recapitalization with Entest CA as the acquirer. As of November 1, 2011 the former stockholder
of Entest CA held approximately 48% of the outstanding common shares of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Upon acquisition of Entest
CA, we abandoned our efforts in the field of active/leisure fashion design clothing. &nbsp;Our business is currently the business
of Entest CA, and we currently intend to develop and commercialize therapies, medical devices and medical testing procedures. On
July 12, 2009 we adopted the name of Entest CA when we changed our name to Entest BioMedical, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The Company&rsquo;s current
strategy is to develop and commercialize therapies, medical devices and medical testing procedures for the veterinary market. &nbsp;It
is believed by the Company that any required regulatory approvals can be obtained much more rapidly with regard to products and
services developed for the veterinary market and that the achievement of successful clinical trials and commercialization of such
products and services may allow the company to enter into collaborations with larger pharmaceutical companies for the purpose of
developing and commercializing these products and services for human usage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The process by which a new drug is approved for use in humans within
the United States generally begins prior to submission of the IND (Investigational New Drug Application) with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Prior to submission of the IND, the sponsor of the drug compound
under development must test the drugs on laboratory animals (preclinical testing) in order that toxicity may be determined and
efficacy may be demonstrated. The results of such preclinical testing is crucial in determining whether or not the sponsor may
proceed onto clinical trials on human beings and preclinical testing is required to be performed on multiple species.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Drug studies in humans can begin only after an IND is reviewed by
the FDA and a local institutional review board (IRB). The board is a panel of scientists and non-scientists in hospitals and research
institutions that oversees clinical research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">IRBs approve the clinical trial protocols, which describe the type
of people who may participate in the clinical trial, the schedule of tests and procedures, the medications and dosages to be studied,
the length of the study, the study's objectives, and other details. IRBs make sure the study is acceptable, that participants have
given consent and are fully informed of their risks, and that researchers take appropriate steps to protect patients from harm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">After trial protocols have been approved the sponsor moves on to
Phase I clinical trials (to determine safety and toxicity in a small number of volunteers) and, if Phase 1 studies don't reveal
unacceptable toxicity, Phase II and Phase III clinical trials to determine effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The process by which a new drug is approved for veterinary &nbsp;use
within the United States generally begins with the sponsor researching &nbsp;and developing &nbsp;the new compound and conducting
&nbsp;initial (&ldquo;pilot&rdquo;) studies on it for a specific use in a specific animal species (called the &ldquo;target animal&rdquo;
species) If the results of the pilot studies are promising and there is a potential market for the drug, the drug sponsor contacts
The US Food and Drug Administration&rsquo;s Center for Veterinary Medicine (CVM) to officially begin the drug approval process
by opening an Investigational New Animal Drug (&ldquo;INAD&rdquo;) file. &nbsp;Information is submitted regarding Chemistry, Manufacturing,
and Controls; Effectiveness; Target Animal Safety; Human Food Safety(if applicable); Environmental Impact (if applicable) and Labeling
in support of the NADA (New Animal Drug Application) which is submitted by the sponsor for approval by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">With the exception of a biologic product which can be classified
as a medical device, &nbsp;Biologics developed for human use generally are undergo the same path to FDA approval as &nbsp;for drugs.
Biologics classified as medical devices may, in most instance, be subject to premarket approval by the FDA. Medical devices intended
for veterinary use are not subject to premarket approval by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Veterinary Biologics are regulated by the U.S. Department of Agriculture
(USDA) &nbsp;which is authorized, under the 1913 Virus-Serum-Toxin Act as amended by the 1985 Food Security Act, to ensure that
all veterinary biologics produced in, or imported into, the United States are not worthless, contaminated, dangerous, or harmful.
The Veterinary Biologics Program of the USDA's Animal and Plant Health Inspection Service (APHIS) oversees the veterinary biologics
industry in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Domestic manufacturers of veterinary biologics, for domestic use
or for export, are required to possess a valid U.S. Veterinary Biologics Establishment License and an individual U.S. Veterinary
Biologics Product License for each product produced for sale. &nbsp;Prior to being granted a U.S. Veterinary Biologic Establishment
License, the applicant must submit detailed information regarding the facilities and the qualifications of key personnel and must
submit to an inspection of the facilities by the Center for Veterinary Biologics, a division of the USDA . To qualify for an establishment
license, an applicant also must qualify for at least one product license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Prior to being granted a U.S. Veterinary Biologics Product License,
the applicant must submit detailed information including test reports and research data sufficient to establish purity, safety,
potency and efficacy of the product, an Outline of Production, and information regarding labeling and &nbsp;facilities that are
to be used in preparation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">It is the Company&rsquo;s opinion that factors such as the lack
of need for multispecies pre clinical testing, smaller subject size in efficacy testing (subjects generally &nbsp;in the hundreds
for veterinary equivalent of Phase III clinical trials as opposed to generally &nbsp;in the thousands for Phase III clinical trials
for drug compounds for use in humans), lack of the requirement for premarket approval &nbsp;for medical devices intended for veterinary
use should generally lead to a shorter timeframe for approval by the appropriate regulators of drugs, biologics, and medical devices
intended for veterinary use as opposed to drugs, biologics, and medical devices intended for human use.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The Company is currently focusing
its efforts and allocating its resources towards:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify"><FONT STYLE="background-color: white">(a)
The development and commercialization of ImenVax&trade;, a therapeutic cancer vaccine for use in canines</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify"><FONT STYLE="background-color: white">(b)
The acquisition of veterinary clinics</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt">The Company is
attempting to acquire currently existing veterinary clinics so that it may benefit from:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-align: justify; margin-bottom: 0pt">(a) Cash flow generated from operations during
the development stage of the Company&rsquo;s products and services,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-align: justify; margin-bottom: 0pt">(b) Utilization of the clinics for clinical
testing,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-align: justify; margin-bottom: 0pt">(c) Utilization of the clinics as a distribution
channel for the Company&rsquo;s products and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt">On January 4, 2011,
2010, Entest CA acquired from Pet Pointers, Inc. ( a California corporation doing business as McDonald Animal Hospital) and Dr.
Gregory McDonald DVM all the goodwill from Dr. McDonald and assets of Pet Pointers, Inc except cash and accounts receivables used
in connection with the operation of a veterinary medical clinic located at 225 S. Milpas Street, Santa Barbara, CA 93103 which
conducts business under the name McDonald Animal Hospital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">Consideration for the acquisition consisted
of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-indent: 0pt; margin-bottom: 0pt; text-align: justify">I. $70,000 in cash</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-indent: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify; text-indent: -60pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-indent: 0pt; margin-bottom: 0pt; text-align: justify">II. $210,000 of the common
shares of the Company valued at the closing price per share as of January 4, 2011</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-indent: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify; text-indent: -60pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-indent: 0pt; margin-bottom: 0pt; text-align: justify">III.
Payment of no more than $78,000 to a creditor of the sellers to be paid in monthly installments of $1,500 per month</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify; text-indent: -60pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-indent: 0pt; margin-bottom: 0pt; text-align: justify">IV.
Payment of no more than $25,000 to additional creditors of the sellers to be paid in monthly installments of $825 per month</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify; text-indent: -60pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-indent: 0pt; margin-bottom: 0pt; text-align: justify">V. Payment of $50,000
to Dr. McDonald on the first business day of the fourth month following the closing of the acquisition (&ldquo;Closing&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">The Company also became obligated to make
payment to Dr. McDonald of that number of shares of common stock of the Company&rsquo;s common stock valued at the closing bid
price of the trading day immediately prior to issuance which shall equal $70,000 upon completion of the first calendar year during
the Employment Period (as such period is defined in the employment agreement entered into between McDonald and Entest CA dated
December 31, 2010 ) in which the business acquired generates gross sales in excess of $700,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt">The payment of $50,000
due to Dr. McDonald was satisfied by the Company through the issuance of 143,000 of our common shares to Dr. Gregory McDonald
on August 29, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt">Dr. McDonald was terminated
from his position as Managing Licensee and Supervising Veterinarian of the McDonald Animal Hospital on March 30, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt">On October 10, 2012
a Complaint (&ldquo;Complaint&rdquo;) was filed in the Superior Court of the State of California against the Company and David
Koos by McDonald, a former employee of the Company, alleging breach of contract and breach of the covenant of good faith and dealing
in connection with the assumption of lease obligations by the Company in connection with the acquisition of the assets of Pet
Pointers, Inc breach of contract and breach of the covenant of good faith and dealing in connection with an employment agreement
enters into with McDonald inc connection with the Acquisition, breach of contract in connection with the Acquisition purchase
agreement, breach of the covenant of good faith and dealing in connection with the Acquisition purchase agreement, implied indemnity
in connection to amounts owed by McDonald to Anthony and Judi Marinelli, the Internal Revenue Service, and the California Franchise
Tax Board, intentional misrepresentation, negligent misrepresentation , failure to pay wages and violations of Sections 2802,
203, and 2806 of the California Labor Code. The Complaint sought judgment for nominal damages, actual damages, compensatory damages,
lost wages, compensation, expenses wage benefits and penalties pursuant to California Labor Code Sections 203 et al, 2802 and
2806, indemnification, accrued interest, punitive damages, costs of suit and attorney&rsquo;s fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0pt; text-align: justify; margin-bottom: 0pt">On
November 28, 2012 the &ldquo;Company executed an agreement (&ldquo;Agreement&rdquo;) with Gregory McDonald (&quot;McDonald&quot;),
Pet Pointers, Inc. (&quot;Pet Pointer&quot;) whereby Mc Donald and Pet Pointer would acquire from the Company all assets ( with
the exception of cash and accounts receivable) utilized by the Company in the operation of the McDonald Animal Hospital, a full
service veterinary clinic owned and operated by the Company and located in Santa Barbara, California (&ldquo;McDonald Asset Sale&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0pt; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt">As consideration to the Company for the assets
acquired, McDonald and Pet Pointers provided to the Company a General release whereby McDonald and Pet Pointer waive, release and
discharge the Company and their respective assignees, officers, directors, shareholders, boards, owners, employees, attorneys,
agents, trustors, trustees, beneficiaries, heirs, successors, and representatives from all known and unknown claims, demands, causes
of action, attorney's fees, costs, or expenses including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-align: justify; margin-bottom: 0pt">(1) All claims relating to the Complaint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-align: justify; margin-bottom: 0pt">(2) Those amounts owed by McDonald to Anthony
and Judi Marinelli which the Company became obligated to pay on McDonald&rsquo;s behalf pursuant to the asset purchase agreement
entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-align: justify; margin-bottom: 0pt">(3) Those amounts owed by McDonald
to the Internal Revenue Service which the Company became obligated to pay on McDonald&rsquo;s behalf pursuant to the asset purchase
agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-align: justify; margin-bottom: 0pt">(4) Those amounts owed
by McDonald to the California Franchise Tax Board which the Company became obligated to pay on McDonald&rsquo;s behalf pursuant
to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt">Assets disposed of pursuant to the Agreement
include approximately $4,897 of Property Plant and Equipment net of accumulated depreciation as well as all inventory held at the
McDonald Animal Hospital.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">Assets disposed of pursuant to the Agreement
also include</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify">(i) Essentially all intellectual property,
including computer software, utilized in connection with the operation of the McDonald Animal Hospital</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify">(ii) All telephone numbers, fax numbers, service
marks, trademarks, trade names, fictitious business names, websites, business email addresses, vendor lists, promotional materials,
vendor records and any and all business records including, but not limited to, such items stored in computer memories, microfiche,
paper record or by any other means relevant to the operation of the McDonald Animal Hospital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; text-align: justify; margin-bottom: 0pt">(iii) All customer lists, customer contacts,
and any and all customer records that are related to the McDonald Animal Hospital.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt">As a result of the agreement, the Company
anticipates recording a non-cash pre-tax charge for the impairment of goodwill recorded in connection with the acquisition of the
McDonald Animal Hospital of approximately $405,000 for the quarter ended November 30, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">Pursuant to the Agreement, the Company became
obligated to make payment of $13,000 within five days of the Closing of the Agreement as such term is defined in the Agreement.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">Pursuant to the Agreement, the Company agrees
to waive, release and discharge McDonald and Pet Pointer from all known and unknown claims, demands, causes of action, attorney's
fees, costs, or expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">Pursuant to the Agreement, the Company agrees
not to engage in a competing business within a 5 mile radius of the property currently housing the McDonald Animal Hospital for
three years.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">The acquisition of existing veterinary clinics
/ hospitals remains an integral part of the Company&rsquo;s business plan. At this time, the company is seeking to identify and
acquire veterinary practices existing and operating within the areas of San Diego, California and Orange County, California .The
Company believes that these areas are close enough in proximity the Company&rsquo;s headquarters to allow ease of interaction with
the Company's management . In addition, the Company believes owning and operating veterinary clinics within the San Diego, California
and Orange County , California areas will provide greater convenience for persons involved with the Company's research and development
activities who may be required to utilitize those facilities. The company is currently in discussions with entities it believes
can expedite local clinic acquisitions.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: black">The Company has not
undertaken any discussions with any pharmaceutical companies regarding the commercialization of any products under development.
None of the Company&rsquo;s products have been approved by any regulatory body for marketing within the United States or anywhere
else. No assurance can be given that all or any of the Company&rsquo;s currently planned products will ever be commercialized.
Therapies which are veterinary biologics may be administered to patients of veterinary clinics that may be acquired prior to licensure
under the exemption provided by 9 CFR 107.1, which exempts a veterinary biologic from Federal regulation if the product was manufactured
by veterinarians AND intended solely for use with their clients' animals under a veterinarian-client-patient (VCP) relationship.</FONT><FONT STYLE="font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Principal Products and Services</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 8pt">Th</FONT><FONT STYLE="font-size: 10pt; color: black; background-color: white">e
Company is currently focusing its research and development efforts toward the successful development and commercialization of the
ImenVax family of canine cancer vaccines as well as the acquisition of existing veterinary clinics / hospitals to be utilized as
potential distribution channels for its ImenVax family of canine cancer vaccines. The Company believes that, in addition to serving
as distribution channels for the Company&rsquo;s immuno-therapeutic cancer vaccine for canines, these clinics will be able to generate
revenue for the Company from current operations. It is anticipated by the Company that data collected from canine cancer treatment
will provide support for eventual use of this therapy in humans and such therapy may be developed and commercialized by the Company
in collaboration with larger and better capitalized pharmaceutical companies.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">ImenVax&trade; I</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">ImenVax&trade; I, currently under development by the Company,
is a therapeutic for canine cancer which involves isolating tumor cells from the patient and then placing the cells into a cell
implant device that is inserted subcutaneously into the patient. &nbsp;The resulting expression of tumor antigens from the device
is intended to generate an anti-tumor immune response. The implant chamber device provokes immune responses to the tumor cells
isolated from the patient&rsquo;s own tumor through a process known as indirect presentation. Tumor cells implanted in the device
are exposed to conditions that are distinct from the tumor&rsquo;s environment from which they were isolated. This altered environment
allows for anti-tumor responses that are not ordinarily observed in the natural tumor progression.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The cells are :</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify">1) Isolated from the tumor and freed from the natural tumor
microenvironment</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify">2) Subjected to an initial ischemic condition of hypoxia
that induces increased antigen expression</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify">3) Allowed to repopulate within the device in a context that
facilitates extended release of tumor antigens.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The device utilized is comprised of a 0.4 micron inner membrane
to retain the implanted cells and an</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">outer 5 micron membrane that allows blood vessels to form
on the surface to enhance biocompatibility. The outer membrane is held in place by a polyester mesh. The membranes are sonically
sealed using a polyester mesh insert.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The device contains a surface architecture that promotes
vascularization in-vivo. There is an initial ischemic phase that may additionally influence the tumor cell growth characteristics
and genetic regulation of the tumor cells.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">It is hypothesized that shortly after implantation, the expression
of immunosuppressive molecules is down regulated while the release of antigens is maintained, thus allowing immune responses to
occur that would normally be suppressed.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Antigens that are released from the implanted device
are taken up by antigen presenting cells (APC).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">It is believed that the APCs will be trained to recognize
the cancer cells and alert the body&rsquo;s immune response, activating antibodies and T cells to destroy the tumor cells.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The Company is currently
conducting a ten dog safety study to Evaluate ImenVax&trade; I for the Treatment of Canine Oral Melanoma and determine adverse
effects, if any. As of May 17, 2012 three dogs suffering from oral melanoma have been administered the therapy with no dog suffering
any material adverse reaction.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Inclusion in the Safety Study is limited to ten dogs with
histologically confirmed canine oral melanoma with a Studied Karnofsky performance status of one or less. The subject are required
to be over &nbsp;eight kg with measurable tumor lesions by caliper or imaging, either primary or metastatic, &nbsp;that may or
may not have had prior non-immunological-based therapy. No concurrent NSAID therapy is allowed and previous use of immune-based
therapies is not permitted. Subjects are required to &nbsp;have a two month life expectancy, and, not have any disease or condition
(other than the cancer) &nbsp;that would preclude living for 3 to 6 months.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Toxicity is evaluated prior to, and after, treatment and
monthly for &nbsp;a period of 3 months. To date, subjects have been recruited solely from patients of the McDonald Animal Hospital
in order that the therapy may be administered licensure under the exemption provided by 9 CFR 107.1, which exempts a veterinary
biologic from Federal regulation if the product was manufactured by veterinarians AND intended solely for use with their clients'
animals under a veterinarian-client-patient (VCP) relationship. To date, 3 dogs have been enrolled in the safety study with none
exhibiting any adverse effects. The Company estimates that an additional $100,000 will be required to be expended to complete the
safety study.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Subsequent to completion of the safety study and pending
favorable results, the Company plans to offer ImenVax&trade; I to its own patients under the exemption provided by 9 CFR 107.1,
which exempts a veterinary biologic from Federal regulation if the product was manufactured by veterinarians AND intended solely
for use with their clients' animals under a veterinarian-client-patient (VCP) relationship subject to the successful acquisition
of one or more veterinary clinics by the Company.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">ImenVax<FONT STYLE="font-family: Arial Unicode MS,sans-serif">&trade;</FONT>&nbsp;II</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Also in early stage development by the Company is a version of ImenVax<FONT STYLE="font-family: Arial Unicode MS,sans-serif">&trade;</FONT>&nbsp;called
ImenVax<FONT STYLE="font-family: Arial Unicode MS,sans-serif">&trade;</FONT>&nbsp;II which utilizes cell lines for sustained release
of immunologically relevant cytokines for maximum anti-tumor immune responses. It is believed by the Company that this controlled
release of cytokines will act as an adjuvant to be combined with patient&rsquo;s tumor cells (antigens) within an implantable membrane
encapsulation device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">ImenVax<FONT STYLE="font-family: Arial Unicode MS,sans-serif">&trade;</FONT>&nbsp;II
is designed to function in a manner similar to ImenVax&trade; I. However, In order to further potentiate the tumor antigen specific
immune responses, the Company intends to include adjuvant cytokine(s) along with tumor cells into the implantation device. &nbsp;&nbsp;The
adjuvants can be added through cytokine expressing cell line. The implantation device to be utilized for administering ImenVax<FONT STYLE="font-family: Arial Unicode MS,sans-serif">&trade;</FONT>&nbsp;II
is expected to be substantially similar to that utilized in administering ImenVax&trade; I.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">ImenVax<FONT STYLE="font-family: Arial Unicode MS,sans-serif">&trade;</FONT>&nbsp;III</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">ImenVax III is intended to function by harnessing the ability of
placental extracts to combat canine cancers. ImenVax&trade;III is intended to treat existing tumors through stimulation of immune
responses to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify">a) kill tumor cells directly;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify">b) indirectly kill tumor cells by cutting off the tumor blood supply;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify">c) block the ability of the tumor to suppress the immune system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Xenogeneic (from different species) antigen induced immunity has
been shown to break self tolerance and capable of engendering immune responses against the endogenous counterpart self<FONT STYLE="font-family: Arial Unicode MS,sans-serif">-</FONT>antigen.
The use of xenogeneic placental derived agents such as VEGF (vascular endothelial growth factor) has demonstrated regression of
soft tissue sarcomas in dogs (Kamstock D, Elmslie R, Thamm D, Dow S. 2007. Evaluation of a xenogeneic VEGF vaccine in dogs with
soft tissue sarcoma. 56(8): 1299<FONT STYLE="font-family: Arial Unicode MS,sans-serif">-</FONT>309). &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">ImenVax<FONT STYLE="font-family: Arial Unicode MS,sans-serif">&trade;</FONT>&nbsp;III
is intended to be an off the shelf formulation , manufactured under GMP, &nbsp;which shall harness the power of trophoblasts (cells
forming the outer layer of a blastocyst, which provide nutrients to the embryo and develop into a large part of the placenta) derived
&nbsp;from human placental tissue to combat canine cancers . No tissue processing is required for the administration of the ImenVax<FONT STYLE="font-family: Arial Unicode MS,sans-serif">&trade;</FONT>&nbsp;III
therapy as opposed to I and II as no cellular material from the patient is utilized.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">ENT-576<FONT STYLE="font-family: Arial Unicode MS,sans-serif">&trade;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">ENT-576<FONT STYLE="font-family: Arial Unicode MS,sans-serif">&trade;</FONT>&nbsp;is
a proprietary therapy being developed by the Company for the treatment of Chronic Obstructive Pulmonary Disease (COPD) such therapy
comprising of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify">a) extracting a therapeutic number of cells from a tissue containing
in part a stem cell population;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify">b) processing said population of cells derived from said tissue
so as to concentrate said stem cell population;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify">c) systemic re-administration of said cell population into the same
patient; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify">d) exposing the patient lung to a sufficient intensity and frequency
of laser irradiation necessary to augment therapeutic activity of said cells in said patient suffering from COPD. The Company has
also considered &nbsp;utilizing an FDA approved biochemical drug to produce the desired augmentation of therapeutic activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">A therapeutic intervention in COPD would require addressing the
issues of inflammation and regeneration. Although approaches such as administration of bone marrow stem cells or fat derived cellular
components have both regenerative and anti-inflammatory activity in animal models, the Company feels &nbsp;that the &nbsp;need
to enhance their potency for clinical applications can be addressed through the usage of low level lasers which studies have demonstrated
&nbsp;may induce growth factor production, inhibit &nbsp;inflammation and &nbsp;stimulate angiogenesis.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">There can be no assurance that approvals required will be
obtained for any of the Company&rsquo;s current therapies under development, or that if such approvals are obtained that the Company
will be able to effectively market its therapies. There can be no assurance given that actual costs and timeframes related to commercialization
for any proposed product will not deviate materially from the Company&rsquo;s estimation. Currently, none of the Company&rsquo;s
products under development may be administered or marketed in the United States or outside of the United states except pursuant
to an exemption from relevant regulation. The Company does not anticipate conducting further research and development related to
ENT-576&trade; until completion of the Safety Study due to limited resources available to the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">Distribution methods of the products
or services:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">The Company intends to distribute
its products and services through several channels including:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; line-height: 115%; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 3%; line-height: 115%; font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="width: 88%; line-height: 115%; font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">utilization of an internal sales force to market directly to veterinary professionals</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="line-height: 115%; font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">distribution through acquired veterinary clinics if and when such clinics are acquired</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="line-height: 115%; font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="line-height: 115%; font-size: 10pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">utilization of contract sales organizations</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On October 19, 2011 the Company
entered into an agreement with RenovoCyte &nbsp;LLC and Medistem Inc. (&ldquo;Agreement&rdquo;) &nbsp;whereby the Company shall
provide research services to RenovoCyte &nbsp;LLC in connection with a ten dog pilot study to determine the safety and effectiveness
of the utilization of stem cell therapy for the treatment of arthritis in animals (&ldquo;Pilot Study&rdquo;). The term of the
Agreement is from October 19, 2011 until the earlier of the completion of the Pilot Study or October 19, 2015 unless terminated
by RenovoCyte LLC due to an event of force majeure exceeding a period of 4 months. As consideration for providing services pursuant
to the Agreement, the Company shall enjoy joint publishing rights with regards to the results of the Pilot Study. &nbsp;Canine
mesenchymal multipotent stem cell injections to be utilized during the course of the Pilot Study shall be provided to the Company
by RenovoCyte LLC at no cost to the Company.</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">As of January 26, 2013 there
have been 8 canine patients treated through the Pilot Study.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Competitive business conditions and Entest's competitive
position in the industry and methods of competition</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">We are recently formed and have yet to achieve revenues or
profits. The animal health pharmaceutical and biologics industries in which we intend to compete are highly competitive and characterized
by rapid technological advancement. Many of our competitors have greater resources than we do. Also, The companion animal healthcare
industry (e.g. veterinary hospitals and veterinarians) although highly fragmented is also highly competitive.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">We intend to be competitive by acquiring veterinary hospitals
to serve as distribution channels for the products and services we produce. We also intend to be competitive by utilizing the services
and advice of individuals that we believe have expertise in their field in order that we can concentrate our resources on projects
in which products and services in which we have the greatest potential to secure a competitive advantage may be developed and commercialized
.</P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">To that effect, we have established a Scientific Advisory
Board of (the Advisory Board) comprised of individuals who we believe have a high level of expertise in their professional fields
and who have agreed to provide counsel and assistance to us in (a) determining the viability of proposed projects (b) obtaining
financing for projects and (c) obtaining the resources required to initiate and complete a project in the most cost effective and
rapid manner. The members of the Advisory Board have also agreed to act as consultants on a project by project basis in addition
to other services they may provide under any other contractual obligations to us.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Members of the Advisory Board include as follows:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Brian Koos, MD:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Brian Koos is Professor and Vice Chair at Obstetrics
and Gynecology at the David Geffen School of Medicine at UCLA, Professor at the Brain Research Institute at the UCLA School of
Medicine, and Director of the Maternal-Fetal Medicine Fellowship (UCLA). Dr. Koos received his MD from Loma Linda University School
of Medicine. Dr. Brian Koos is the brother of David R. Koos, the Company&rsquo;s Chairman, President and CEO.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Koos serves as a member of the Advisory Board pursuant
to an agreement by and between the Company and Bio-Matrix Scientific Group, Inc. entered into on June 19, 2009 whereby the Bio-Matrix Scientific Group, Inc assigned its rights to the services of Dr. Koos to the Company for consideration to Bio-Matrix Scientific
Group of $10,000. Those rights included the services of Dr. Koos as a member of the Company&rsquo;s Advisory Board for a period
ending April 8, 2014.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Steven Josephs, PhD:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Josephs is currently serving as Executive Manager and
Chief Scientific Officer of TherInject LLC, a company involved in the development of pharmaceuticals to be utilized for the treatment
of cancer. Dr. Josephs has 34 years of experience in research and clinical product development and production for biologics, gene
therapy and medical devices.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Josephs has previously served as Director of Research
and Development for Therapheresis, Inc, Head of Virology and Senior Research Scientist for Baxter Healthcare Corporation, and Director
of Molecular Biology at Universal Biotechnology, Inc where Dr. Josephs directed a group performing contract molecular biology services
for government and private industry.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Josephs has also worked for the National Cancer Institute
where his duties included studies of the human T-cell leukemia virus as well as sequence determination and functional analyses
of HIV. Dr. Josephs is the co-discoverer of human herpesvirus-6, the etiologic agent of Roseola.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Josephs holds a B.A. in Chemistry, a Ph.D. in Chemistry
and has been granted a Professional Certificate in Drug Development and an ADMET process certificate by the University of California,
San Diego. Dr. Josephs has also earned a Master of Science in Science Teaching.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Josephs serves as a member of the Advisory Board at will
and at the pleasure of the Board of Directors of the Company. There is no binding agreement by and between the Company and Dr.
Josephs regarding membership on the Advisory Board.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Ewa Carrier, MD:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Carrier is Associate Professor of Clinical Medicine and
Pediatrics, University of California San Diego</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Blood and Marrow Transplant Program.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Carrier has served as principal investigator for the
following clinical protocols:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Protocol For The Use of AMD3100 to Mobilize Peripheral Blood
Stem Cells For Collection and Transplantation - Emergency Compassionate Use, Single Patient IND.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Erythropoietic Differentiation of Human ES Cells.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">CTLA-4 Blockade with MDX-010 to Induce Graft-Versus-Malignancy
Effects Following Allogeneic Hematopoietic Stem Cell Transplantation. (NCI Protocol Number P-6082) (closed to accrual).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Phase 3 Randomized, Open-label Clinical Trial of Tanespimycin
(KOS-953) plus Bortezomib Compared to</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Bortezomib Alone in Patients with Multiple Myeloma in First
Relapse [Protocol KAG-301] [Protocol Version 21-JUL-2007]</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Autologous Stem Cell Transplant for Myasthenia Gravis.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Collection of Bone Marrow from Patients with Multiple Myeloma
for Study of New Therapies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">A Pilot Study of High-Dose Immunosuppression and Autologous
Stem Cell Infusion in Patients with Systemic Lupus</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Erythematosus Refractory to Conventional Therapy (closed
to accrual).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Autologous Stem Cell Transplant for Myasthenia Gravis &ndash;
a retrospective analysis.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Carrier has served as co investigator for the following
clinical protocols:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Pilot Study of Allogeneic Peripheral Blood Progenitor Cell
Transplantation in Patients with Chemotherapy-Refractory or Poor- Prognosis Metastatic Breast Cancer.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Pilot Study of a Non-Myeloablative Preparative-Regimen for
Allogeneic Peripheral Blood Progenitor Cell Transplantation in Patients with Chronic Myeloid and Lymphoid Malignancies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Phase II Study of a Non-Myeloablative Preparative-Regimen
for Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors in Patients with Chronic Myeloid and Lymphoid Malignancies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">A Phase II Study of Tumor-Specific Idiotype (Id) and Soluble
GM-CSF Vaccination Following Autologous Peripheral Blood Stem Cell Transplantation in Patients with Low-Grade Non-Hodgkin's Lymphomas.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Phase II Study of FavId (Tumor-Specific Idiotype-KLH) and
Soluble GM-CSF Immunotherapy in Patients with Stable or Progressive Grade 1 or 2 Follicular B-Cell Lymphomas [FavId01].</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Phase II Trial of Rituxan&reg; plus FavId&trade; (Tumor-Specific
Idiotype-KLH) and GM-CSF Immunotherapy in Patients with Grade 1 or 2 Follicular B-Cell Lymphoma [FavId-04].</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Carrier serves as a member of the Advisory Board at will
and at the pleasure of the Board of Directors of the Company. There is no binding agreement by and between the Company and Dr.
Carrier regarding membership on the Advisory Board</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Feng Lin, MD:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Lin is the Director of Research and Development of Entest
BioMedical, Inc. and has previously served as Director of Research and Development of Bio-Matrix Scientific Group, Inc., the Company&rsquo;s
largest shareholder.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Previously, Dr. Lin was a Senior Research Scientist, Research
&amp; Development with Inovio BC, San Diego and Postdoctoral Fellow in Burnham Institute for Medical Research, La Jolla.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Lin received his M.D. from Central South University Xiangya
School of Medicine, Changsha, China, and received a M.S. Biochemistry &amp; Molecular Biology and a Ph.D. Hematology &amp; Physiology
from the same institution.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Lin serves as a member of the Advisory Board at will
and at the pleasure of the Board of Directors of the Company. There is no binding agreement by and between the Company and Dr.
Lin regarding membership on the Advisory Board.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Vladimir I. Bogin, MD, ABIM:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Bogin is currently the President and CEO of Cromos Pharma,
a contract research organization that specializes in biopharmaceutical clinical outsourcing into Russia and Eastern Europe. From
2008 to 2009 he served as Director of Boehringer Ingelheim (a privately held pharmaceutical company) where he was in charge of
the phase IV program for Dabigatran Etexilate.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Bogin studied medicine at the Yale University School
of Medicine and the University of Rochester School of Medicine and Dentistry.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Bogin serves as a member of the Advisory Board at will
and at the pleasure of the Board of Directors of the Company. There is no binding agreement by and between the Company and Dr.
Bogin regarding membership on the Advisory Board.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Brenda S. Phillips, D.V.M.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Phillips is a veterinary oncologist and co owner of Veterinary
Specialty Hospital of San Diego. She received her Doctor of Veterinary Medicine in 1992 from Michigan State University, College
of Veterinary Medicine.</P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Phillips agreed on January 6, 2011 to serve as a member
of the Advisory Board for a period of 24 months. In connection with that agreement, Dr. Phillips received 10,000 common shares
of the Company.</P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The U.S. market for veterinary
services is highly fragmented. According to the American Veterinary Medical Association, there were more than 51,000 veterinarians
practicing at the end of 2009. The principal factors in a pet owner&rsquo;s decision as to which veterinarian to use include convenient
location and hours, personal recommendations, reasonable fees and quality of care. In order to be competitive in the animal healthcare
industry, we intend to direct our marketing efforts related to clinics , if and when they may be acquired, toward increasing the
number of annual visits from existing clients through customer education efforts and toward attracting new clients through local
print advertising campaigns.</P>

<P STYLE="font: 12pt/1.5pt Times New Roman, Times, Serif; margin: 8.5pt 0 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 0pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white"><B>Sources and availability
of raw materials and the names of principal suppliers</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The supplies and materials
required to conduct our operations are available through a wide variety of sources and may be obtained through a wide variety of
sources.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white"><B>Patents, trademarks,
licenses, franchises, concessions, royalty agreements or labor contracts, including duration</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Entest has not been
granted any patents. Entest is not currently party to any royalty agreements. &nbsp;Entest is not party to any binding labor contracts.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white"><B>Need for any government
approval of principal products or services, effect of existing or probable governmental regulations on the business</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">ImenVax&trade; I and
ImenVax&trade; II are Veterinary Biologics. The U.S. Department of Agriculture (USDA) is authorized under the 1913 Virus-Serum-Toxin
Act to ensure that all veterinary biologics produced in, or imported into, the United States are not worthless, contaminated, dangerous,
or harmful. The Veterinary Biologics Program of the USDA's Animal and Plant Health Inspection Service (&ldquo;APHIS&rdquo;) oversees
the veterinary biologics industry in the United States.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Domestic manufacturers
of veterinary biologics, for domestic use or for export, are required to possess a valid U.S. Veterinary Biologics Establishment
License and an individual U.S. Veterinary Biologics Product License for each product produced for sale.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Prior to being granted
a U.S. Veterinary Biologics Product License, the applicant must submit detailed information including test reports and research
data sufficient to establish purity, safety, potency and efficacy of the product, an Outline of Production, and information regarding
labeling and &nbsp;facilities that are to be used in preparation.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Prior to being granted
a U.S. Veterinary Biologic Establishment License, the applicant must submit detailed information regarding the facilities and the
qualifications of key personnel and must submit to an inspection of the facilities by the Center for Veterinary Biologics, a division
of the USDA. To qualify for an establishment license, an applicant also must qualify for at least one product license.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">In the event that a
veterinary clinic or clinics can be acquired, the Company plans to attempt to distribute ImenVax&trade; I prior to licensure under
the exemption provided by 9 CFR 107.1, which exempts a veterinary biologic from Federal regulation if the product was manufactured
by veterinarians AND intended solely for use with their clients' animals under a veterinarian-client-patient (VCP) relationship.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">ENT-576&trade; can
be considered a &ldquo;combination product&rdquo; whose primary mode of action is through animal stem cells (a veterinary biologic)
It is intended that the Company will obtain a U.S. Veterinary Biologics Establishment License and a U.S. Veterinary Biologics Product
License from the U.S. Department of Agriculture. ENT-576&trade; can also be administered without license if administered in accordance
with the safe harbor provided by 9 CFR 107.1.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">ImenVax&trade; III
can be considered a combination product whose primary mode of action is generated through trophoblasts derived from human placental
tissue. Entest will be required to obtain approval from the US Food and Drug Administration (FDA) in order to market ImenVax&trade;
III. Entest will apply for an Investigational New Animal Drug exemption (INAD) in order that the product may be shipped for testing
and trials and will submit a New Animal Drug Application for ImenVax&trade; III.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The practice of veterinary
medicine is primarily subject to State regulation. The Company will be required to comply with the statutes rules and regulations
of the State in which an acquired veterinary clinic is located. Within the State of California, where the Company is focusing its
acquisition efforts , &nbsp;the practice of veterinary medicine &nbsp;is primarily governed pursuant to The California Veterinary
Medicine Practice Act (CA Bus.&amp; Prof. Code &sect; 4800 et seq.).</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white"><B>Amount spent during
the last fiscal year on research and development activities</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">During the fiscal year
ended August 31, 2012 we expended $5,798 on research and development activities.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify"><B>Costs and effects of compliance
with environmental laws (federal, state and local);</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">Entest has&nbsp;not incurred any
unusual or significant costs to remain in compliance with any environmental laws and does not expect to incur&nbsp;any unusual
or significant costs to remain in compliance with any environmental laws in the foreseeable future.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify"><B>Number of total employees and
number of full-time employees</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">As of January 26, 2013, Entest has
_____ employees of which _____ are full time.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white"><B>Item 2. Properties</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On November 1, 2011, the Company
entered into an agreement to lease approximately 2,320 square feet of office space beginning December 1, 2011 for a period of five
years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Rent to be charged to the
Company pursuant to the lease is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">$2,996 per month for the period
beginning December 1, 2011 and ending November 30, 2012</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">$3,116 per month for the period
beginning December 1, 2012 and ending November 30, 2013</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">$3,241 per month for the period
beginning December 1, 2013 and ending November 30, 2014</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">$3,371 per month for the period
beginning December 1, 2014 and ending November 30, 2015</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">$3,506 per month for the period
beginning December 1, 2015 and ending November 30, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">This property is utilized
as office space. The Company believes that the foregoing property is adequate to meet its current needs. While it is anticipated
that the Company will require access to laboratory facilities in the future, the Company believes that access to such facilities
are available from a variety of sources.</FONT></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Item 3. Legal Proceedings</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On February 3, 2011,
a Complaint (&ldquo;Complaint&rdquo;) was filed in the U.S. District Court Middle District of the State of Pennsylvania against
the Company, the Company&rsquo;s Chairman and BMSN. by 18KT.TV LLC (&ldquo;Plaintiffs&rdquo;) seeking to recover general damages
from the Company. in excess of $125,000. The Complaint alleges breach of contract and unjust enrichment relating to an investor
relations contract executed by the Company and Craig Fischer (on behalf of 18KT.TV LLC). The Complaint also seeks similar damages
from BMSN. The Company believes that the allegations in the complaint are without merit and intends to vigorously defend its interests
in this matter. At this time, it is not possible to predict the ultimate outcome of these matters.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On May 24, 2012, a Complaint (&ldquo;Complaint&rdquo;) was
filed in the U.S. Bankruptcy Court for the District of Oregon against the Company by Titterington Veterinary Services Inc. (&ldquo;TVS&rdquo;).
The Complaint is an adversary proceeding filed by TVS arising from TVS&rsquo;s bankruptcy case currently pending in U.S. Bankruptcy
Court for the District of Oregon. The Complaint alleges Breach of Contract resulting from the Company&rsquo;s alleged failure to
pay certain expenses the Company was required to pay pursuant to an agreement with TVS, Dr. Ronald Titterington, DVM and Dr. Kathy
Snell, DVM (&ldquo;TVS Agreement&rdquo;). TVS is seeking a judgment and money award against the Company in an amount to be proven
at trial which TVS estimates in the Complaint to be up to $50,000. TVS is also seeking a judgment and order against the Company
to provide an accounting of all revenues received by the Company pursuant to the TVS Agreement, all expenses paid, unpaid, and
due and owing &nbsp;pursuant to the TVS Agreement as well as a revenue share which TVS claims is due them pursuant to the TVS Agreement.
TVS is also seeking a judgment requiring the Company to turn over a sum of money equal to expenses the Company was obligated to
pay pursuant to the TVS Agreement. TVS is also seeking attorney&rsquo;s fees and expenses. &nbsp;The Company believes that the
allegations in the complaint are without merit and intends to vigorously defend its interests in this matter. At this time, it
is not possible to predict the ultimate outcome of these matters and an outcome unfavorable to the Company may have a material
adverse effect on the Company. On September 19, 2012 the Plaintiff&rsquo;s Claim for Relief for turnover and an accounting under
11 U.S.C. &sect; 542 and the Plaintiff's Claim for Relief for attorney fees were dismissed with prejudice and , as per the claim
of breach of contract, the proceeding was transferred to the United States Bankruptcy Court for the District of Southern California
for all further proceedings.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On October 10, 2012 a Complaint(&ldquo;Complaint&rdquo;)
was filed in the Superior Court of the State of California against the Company and David Koos by Dr. Gregory McDonald, a former
employee of the Company, alleging breach of contract and breach of the covenant of good faith and dealing in connection with the
assumption of lease obligations by the Company in connection with the acquisition of the assets of Pet Pointers, Inc (&ldquo;Acquisition&rdquo;)
(Note 9) breach of contract and breach of the covenant of good faith and dealing in connection with an employment agreement enters
into with Dr. McDonald inc connection with the Acquisition, breach of contract in connection with the Acquisition purchase agreement,
breach of the covenant of good faith and dealing in connection with the Acquisition purchase agreement, implied indemnity in connection
to amounts owed by Dr. McDonald to Anthony and Judi Marinelli, the Internal Revenue Service, and the California Franchise Tax Board,
intentional misrepresentation, negligent misrepresentation , failure to pay wages and violations of Sections 2802, 203, and 2806
of the California Labor Code. The Complaint seeks judgment for nominal damages, actual damages, compensatory damages, lost wages,
compensation, expenses wage benefits and penalties pursuant to California Labor Code Sections 203 et al, 2802 and 2806, indemnification,
accrued interest, punitive damages, costs of suit and attorney&rsquo;s fees.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">On November 28, 2012, a settlement of the
aforementioned Complaint, the &ldquo;Company executed an agreement (&ldquo;Agreement&rdquo;) with Gregory McDonald (&quot;McDonald&quot;),
Pet Pointers, Inc. (&quot;Pet Pointer&quot;) whereby Mc Donald and Pet Pointer would acquire from the Company all assets ( with
the exception of cash and accounts receivable) utilized by the Company in the operation of the McDonald Animal Hospital (&ldquo;McDonald
Asset Sale&rdquo;).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">As consideration to the Company for the assets
acquired, McDonald and Pet Pointers provided to the Company a General release whereby McDonald and Pet Pointer waive, release and
discharge the Company and their respective assignees, officers, directors, shareholders, boards, owners, employees, attorneys,
agents, trustors, trustees, beneficiaries, heirs, successors, and representatives from all known and unknown claims, demands, causes
of action, attorney's fees, costs, or expenses including:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify">(1)
All claims relating to the Complaint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify">(2)
Those owed by McDonald to Anthony and Judi Marinelli which the Company became obligated to pay on McDonald&rsquo;s behalf
pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify">(3)
Those amounts owed by McDonald to the Internal Revenue Service which the Company became obligated to pay on McDonald&rsquo;s
behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers,
Inc</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify">(4)
Those amounts owed by McDonald to the California Franchise Tax Board which the Company became obligated to pay on
McDonald&rsquo;s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and
Pet Pointers, Inc</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">Assets disposed of pursuant to the Agreement
include all Property Plant and Equipment as well as all inventory held at the McDonald Animal Hospital.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">Assets
disposed of pursuant to the Agreement also include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify">(i)
Essentially all intellectual property, including computer software, utilized in connection with the operation of the McDonald
Animal Hospital</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify">(ii)
All telephone numbers, fax numbers, service marks, trademarks, trade names, fictitious business names, websites, business
email addresses, vendor lists, promotional materials, vendor records and any and all business records including, but not
limited to, such items stored in computer memories, microfiche, paper record or by any other means relevant to the operation
of the McDonald Animal Hospital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 40pt; margin-bottom: 0pt; text-align: justify">(iii)
All customer lists, customer contacts, and any and all customer records that are related to the McDonald Animal Hospital.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On January 15, 2013 the Company received from Asher Enterprises,
Inc.(&ldquo;Asher&rdquo;) a written demand for payment of $189,000 ( representing 150% of the outstanding principal balance) plus
accrued interest at the Default rate of interest which is 22% per annum. The Demand stems from Asher&rsquo;s assertion that the
Company has defaulted on provisions in two Convertible Notes in the principal amounts of $63,000 per note issued by the Company
to Asher as a result of the Company&rsquo;s failure to comply with the reporting requirements of the Securities and Exchange Act
of 1934. Collectively the amount of $189,000 plus accrued interest at the Default rate of interest which is 22% per annum may be
referred to as the Default Amount</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Pursuant to the terms and conditions of the two notes, in
the Event that the Company fails to pay the Default Amount within five business days of written notice that such amount is due
and payable, then the Asher shall have the right at any time, so long as the Company remains in default (and so long and to the
extent that there are sufficient authorized shares), to require the Company, upon written notice, to immediately issue, in lieu
of the Default Amount, the number of shares of Common Stock of the Company equal to the Default Amount divided by the Conversion
Price then in effect pursuant to the terms and conditions of the notes.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Item 4. Submission of Matters to a Vote of Security Holders</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">No matter was submitted during the fourth quarter of the
fiscal year covered by this report to a vote of security holders, through the solicitation of proxies or otherwise.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>PART II</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Item 5. Market for Registrant&rsquo;s Common Equity, Related
Stockholder Matters and Issuer Purchases of Equity Securities</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Company&rsquo;s&nbsp;common stock is a &quot;penny stock,&quot;
as defined in Rule 3a51-1 under the Exchange Act. The penny stock rules require a broker-dealer, prior to a transaction in a penny
stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny
stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current
bid and offer quotations for the penny stock, the compensation of the broker-dealer and its sales person in the transaction, and
monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny
stock rules require that the broker-dealer, not otherwise exempt from such rules, must make a special written determination that
the penny stock is suitable for the purchaser and receive the purchaser's written agreement to the transaction. These disclosure
rules have the effect of reducing the level of trading activity in the secondary market for a stock that becomes subject to the
penny stock rules. So long as the common stock of the Company is subject to the penny stock rules, it may be more difficult to
sell common stock of the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Company&rsquo;s&nbsp;authorized capital stock consists
of 2,000,000,000 shares of common stock with a par value $0.001, and 5,000,000 shares of preferred stock with a par value $0.001 per
share.&nbsp;&nbsp;As of November 1, 2011 there are 20,890,501 shares of common stock issued and outstanding and 5,000 shares of
Series AA preferred stock issued and outstanding.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">(a) Our common stock is traded on the OTCQB Tier of OTC Markets
under the symbol &quot;ENTB&rdquo;. Prior to August 11, 2009&nbsp;there was no established trading market for our common stock.&nbsp;
From August 11, 2009 to February 23, 2011 our common stock traded primarily on the OTCBB. &nbsp;Below is the range of high and
low bid information for our common equity for each quarter within the last two fiscal years. These quotations reflect inter-dealer
prices, without retail mark-up, mark-down or commission and may not represent actual transactions.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 1.6pt; line-height: 115%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">September 1, 2011 to August 31, 2012</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 3pt double; padding-right: 0.05in; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">High</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 3pt double; padding-right: 0.05in; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Low</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 78%; padding-right: 1.6pt; text-align: left; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">First Quarter</FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 1.6pt; line-height: 115%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 8%; padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.598</FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-right: 1.6pt; line-height: 115%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 8%; padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.1387</FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 1.6pt; text-align: left; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Second Quarter</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.100</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.03</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 1.6pt; text-align: left; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Third Quarter</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.034</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.0017</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 1.6pt; text-align: left; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fourth Quarter</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; line-height: 115%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.0225</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; line-height: 115%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.0025</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 1.6pt; line-height: 115%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">September 1, 2010 to August 31, 2011</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 3pt double; padding-right: 0.05in; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">High</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 3pt double; padding-right: 0.05in; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Low</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 1.6pt; text-align: left; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">First Quarter</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; line-height: 115%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.30</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; line-height: 115%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.52</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 1.6pt; text-align: left; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Second Quarter</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.190</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.250</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-right: 1.6pt; text-align: left; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Third Quarter</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.900</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%; text-align: right">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.180</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 1.6pt; text-align: left; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fourth Quarter</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; line-height: 115%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.1730</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD>
    <TD STYLE="padding-right: 1.6pt; line-height: 115%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="padding-right: 1.6pt; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0.390</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; line-height: 115%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Holders</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of August 31, 2012 there were approximately 339 holders
of our Common Stock.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Dividends</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">No cash dividends were paid during the fiscal year ending
August 31, 2012. We do not expect to declare cash dividends in the immediate future. On March 6, 2012 a dividend of 3,201,397 shares
of Series B Preferred Stock was paid to the Company&rsquo;s common shareholders of record as of February 21, 2012.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Recent Sales of Unregistered Securities</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">For the Fiscal Year Ended August 31, 2012:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Shares issued for Services:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On October 7, 2011 the Company issued 50,000 shares of common
stock (&ldquo;Shares&rdquo;) to a consultant for services rendered.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. &nbsp;No commission or other consideration was paid in connection with the sale of the shares. There was
no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate
that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the
restrictions on transferability and sale of the Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On November 22, 2011 the Company issued 18,333 shares of
common stock (&ldquo;Shares&rdquo;) to a consultant for services rendered.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. &nbsp;No commission or other consideration was paid in connection with the sale of the shares. There was
no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate
that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the
restrictions on transferability and sale of the Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On January 10 , 2012 the Company issued 27,499 shares of
common stock (&ldquo;Shares&rdquo;) to a consultant for services rendered.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. &nbsp;No commission or other consideration was paid in connection with the sale of the shares. There was
no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate
that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the
restrictions on transferability and sale of the Shares.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On February 26, 2012 the Company issued 174,663 shares of
common stock (&ldquo;Shares&rdquo;) to a consultant for services rendered.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. &nbsp;No commission or other consideration was paid in connection with the sale of the shares. There was
no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate
that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the
restrictions on transferability and sale of the Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On March 14, 2012 the
Company issued 3,000,000 shares of its common stock (&ldquo;Shares&rdquo;) to the order of Capital Path Securities LLC for acting
as the Company&rsquo;s exclusive advisor and placement agent in connection with the Equity Purchase Agreement and Registration
Rights Agreement entered into by and between the Company and Southridge Partners II, LP (&ldquo;Southridge&rdquo;) on February
27, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. &nbsp;No commission or other consideration was paid in connection with the sale of the shares. There was
no advertisement or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">A legend was placed on the
certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring
to the restrictions on transferability and sale of the Shares.</FONT></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 3, 2012 the Company issued 50,000,000 shares of
common stock (&ldquo;Shares&rdquo;) to David R. Koos as a bonus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">A legend was placed on the certificate that evidences the
Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability
and sale of the Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">David Koos may not offer to sell, sell, transfer, pledge
or otherwise dispose of the Bonus Shares prior to April 2, 2017 (&ldquo;Restricted Period&rdquo;).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">In the event that, prior to the expiration of the Restricted
Period, David Koos voluntarily ceases to be employed at the Company or is terminated for cause the Shares shall be forfeited.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 3, 2012 the Company issued 27,000,000 shares of
common stock (&ldquo;Shares&rdquo;) to seven employees as bonuses.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">A legend was placed on the certificate that evidences the
Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability
and sale of the Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">No employee may offer to sell, sell, transfer, pledge or
otherwise dispose of the Bonus Shares prior to April 2, 2017 (&ldquo;Restricted Period&rdquo;).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">In the event that, prior to the expiration of the Restricted
Period, any employee voluntarily ceases to be employed at the Company or is terminated for cause his or her Shares shall be forfeited.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 3, 2012 the Company issued 15,000,000 shares of
common stock (&ldquo;Shares&rdquo;) to Joseph G. Vaini as bonus.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">A legend was placed on the certificate that evidences the
Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability
and sale of the Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Joseph G. Vaini may not offer to sell, sell, transfer, pledge
or otherwise dispose of the Shares prior to April 2, 2017 (&ldquo;Restricted Period&rdquo;).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">In the event that, prior to the expiration of the Restricted
Period, Joseph G. Vaini declines to provide if requested to provide, or is unable to provide if requested to provide, consulting
services to the Company of a nature that have been customarily provided by Joseph G. Vaini to the Company the Shares shall be forfeited.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On March 27, 2012 the Company issued 75,000 shares of its
nonvoting convertible preferred stock to Southridge in accordance with the terms of the Equity Purchase Agreement entered into
by and between the Company and Southridge on February 27, 2012..</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">A legend was placed on the certificate that evidences the
Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability
and sale of the Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Shares issued for Intangible Assets:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On November 11, 2011 the Company issued 2,500,000 shares
of common stock (&ldquo;Shares&rdquo;) in connection with rights to receive future revenues of a Utah veterinary clinic.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">A legend was placed on the certificate that evidences the
Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability
and sale of the Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Shares Issued for Debt:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On November 28, 2011 the Company issued 134,983 shares of
common stock (&ldquo;Shares&rdquo;) in satisfaction of $12,000 principal amount of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On December 12, 2011 the Company issued 258,824 shares of
common stock (&ldquo;Shares&rdquo;) in satisfaction of $11,000 principal amount of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On December 19, 2011 the Company
issued 338,983 shares of common stock (&ldquo;Shares&rdquo;) in satisfaction of $12,000 principal amount of Convertible Notes Payable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. &nbsp;No commission or other consideration was paid in connection with the sale of the shares. There was
no advertisement or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On January 27, 2012 the Company issued 227,963 shares of common
stock (&ldquo;Shares&rdquo;) in satisfaction of $7,500 principal amount of Convertible Notes Payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. &nbsp;No commission or other consideration was paid in connection with the sale of the shares. There was
no advertisement or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">On February 3, 2012 the Company issued 528,821
shares of common stock (&ldquo;Shares&rdquo;) in satisfaction of $15,000 principal amount of Convertible Notes Payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">The Shares were issued pursuant to Section
4(2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares
were sold directly through our management. No commission or other consideration was paid in connection with the sale of the shares.
There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">On February 16, 2012 the Company issued 721,154
shares of common stock (&ldquo;Shares&rdquo;) in satisfaction of $15,000 principal amount of Convertible Notes Payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">On March 7, 2012 the Company issued 2,322,695
shares of common stock (&ldquo;Shares&rdquo;) in satisfaction of $32,750 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">On March 21, 2012 the Company issued 1,886,195
shares of common stock in satisfaction of $25,200 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">On March 26, 2012 the Company issued 3,017,502
shares of common stock (&ldquo;Shares&rdquo;) in satisfaction of $24,650 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 2, 2012 the Company issued 1,675.111 shares of common
stock (&ldquo;Shares&rdquo;) in satisfaction of $7,538 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 3, 2012 the Company issued 1,590, 909 shares of
common stock (&ldquo;Shares&rdquo;) in satisfaction of $7,000 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 10, 2012 the Company issued 5,555,555 shares of
common stock (&ldquo;Shares&rdquo;) in satisfaction of $10,000 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 12, 2012 the Company issued 4,722,222 shares of
common stock (&ldquo;Shares&rdquo;) in satisfaction of $8,500 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 13, 2012 the Company issued 8,250,000 shares of
common stock (&ldquo;Shares&rdquo;) in satisfaction of $14,850 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 16, 2012 the Company issued 11,250,000 shares of
common stock (&ldquo;Shares&rdquo;) in satisfaction of $18,000 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 18, 2012 the Company issued 1,250,000 shares of
common stock (&ldquo;Shares&rdquo;) in satisfaction of $2,000 of Convertible Notes Payable</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 19, 2012 the Company issued 2,724,968 shares of
common stock (&ldquo;Shares&rdquo;) in satisfaction of $4,300 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 24, 2012 the Company issued 4,005,787 shares of
common stock (&ldquo;Shares&rdquo;) in satisfaction of $6,922 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On May 1, 2012 the Company issued 8,000,000 shares of common
stock (&ldquo;Shares&rdquo;) in satisfaction of $12,000 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On May 3, 2012 the Company issued 7,142, 857 shares of common
stock (&ldquo;Shares&rdquo;) in satisfaction of $10,000 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On May 7, 2012 the Company issued 6,250,000 shares of common
stock (&ldquo;Shares&rdquo;) in satisfaction of $10,000 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On May 9, 2012 the Company issued 5,000,000 shares of common
stock (&ldquo;Shares&rdquo;) in satisfaction of $500 of principal indebtedness of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On June 20, 2012 the company issued 19,054,140 common shares
(&ldquo;Shares&rdquo;) in satisfaction of $75,842 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On June 25, 2012 the company issued 1,808,172 common shares
(&ldquo;Shares&rdquo;) in satisfaction of $6,627 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On August 9, 2012 the Company issued 15,976,380 common shares
(&ldquo;Shares&rdquo;) in satisfaction of $19,880 of Convertible Notes Payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On October 17, 2012 the Company issued 23,000,000 common shares
(&ldquo;Shares&rdquo;) in satisfaction of $19,320 of outstanding convertible indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On October 22, 2012 the Company issued 10,810,811 common shares(&ldquo;Shares&rdquo;)
in satisfaction of $8,000 of outstanding convertible indebtedness.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Shares issued for interest:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On January 27, 2012 the Company issued 51,672 common shares
(&ldquo;Shares&rdquo;) in satisfaction of $1,700 of interest accrued but unpaid.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 10, 2012 the Company issued 833,333 common shares
(&ldquo;Shares&rdquo;) in satisfaction of $1,500 of interest accrued but unpaid.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 18, 2012 the Company issued 875,000 common shares
(&ldquo;Shares&rdquo;) in satisfaction of $1,400 of interest accrued but unpaid.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On May 9, 2012 the Company issued 1,300,000 common shares
(&ldquo;Shares&rdquo;) in satisfaction of $1,300 of interest accrued but unpaid.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Shares issued pursuant to Contractual Obligations:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 11, 2012 the Company issued 1029679 common
shares (&ldquo;Shares&rdquo;) pursuant to contractual obligations contained in certain convertible notes outstanding.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 11, 2012 the Company issued 2,306,275 common
shares (&ldquo;Shares&rdquo;) pursuant to contractual obligations contained in certain convertible notes outstanding.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 13, 2012 the Company issued 2,430,753 common
shares (&ldquo;Shares&rdquo;) pursuant to contractual obligations contained in certain convertible notes outstanding.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On August 2, 2012 the Company issued 1,536,948 common
shares (&ldquo;Shares&rdquo;) pursuant to contractual obligations contained in certain convertible notes outstanding.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Shares were issued pursuant to Section 4(2) of the Securities
Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The shares were sold directly
through our management. No commission or other consideration was paid in connection with the sale of the shares. There was no advertisement
or general solicitation made in connection with this Offer and Sale of Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Issuance of Convertible Debentures:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On October 25, 2011,
the Company issued a convertible promissory note in the amount of $32,500. The note bears an interest rate of eight percent (8%),
matures on July 27, 2012 and may be converted after 180 days from execution of this note for shares of the Company&rsquo;s common
stock. The note may be converted at a fifty two percent (52%) discount to the average of the lowest 3 closing bid prices of the
common stock during the 10 trading days prior to the conversion date. </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The securities were issued pursuant to Section 4(2)
of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The securities
were sold directly through our management. No commission or other consideration was paid in connection with the sale of the securities.
There was no advertisement or general solicitation made in connection with this Offer and Sale of securities.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The note contained a provision that until such time as the
shares of common stock issuable upon conversion of the Note have been registered under the Act or otherwise may be sold pursuant
to Rule 144 without any restriction as to the number of securities as of a particular date that can then be immediately sold,
each certificate for shares of common stock issuable upon conversion of the note &nbsp;that has not been so included in an effective
registration statement or that has not been sold pursuant to an effective registration statement or an exemption that permits
removal of the legend, shall bear a restrictive legend.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On December 19, 2011,
the Company issued a convertible promissory note in the amount of $37,500. The note bears an interest rate of eight percent (8%),
matures on September 21, 2012 and may be converted after 180 days from execution of this note for shares of the Company&rsquo;s
common stock. The note may be converted at a fifty two percent (52%) discount to the average of the lowest 3 closing bid prices
of the common stock during the 10 trading days prior to the conversion date. </FONT></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The securities were issued pursuant to Section 4(2)
of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The securities
were sold directly through our management. No commission or other consideration was paid in connection with the sale of the securities.
There was no advertisement or general solicitation made in connection with this Offer and Sale of securities.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The note contained a provision that until such time as the shares
of common stock issuable upon conversion of the Note have been registered under the Act or otherwise may be sold pursuant to Rule
144 without any restriction as to the number of securities as of a particular date that can then be immediately sold, each certificate
for shares of common stock issuable upon conversion of the note &nbsp;that has not been so included in an effective registration
statement or that has not been sold pursuant to an effective registration statement or an exemption that permits removal of the
legend, shall bear a restrictive legend.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On December 20, 2011
the Company amended the terms of $30,000 in existing debt as follows:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-indent: 0pt; text-align: justify"><FONT STYLE="background-color: white">(a)
&nbsp;Due and payable December 31, 2012</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-indent: 0pt; text-align: justify"><FONT STYLE="background-color: white">(b)
&nbsp;Simple interest of 10% from December 20, 2011 to the date the debt is fully converted or paid in full</FONT>&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-indent: 0pt; text-align: justify"><FONT STYLE="background-color: white">(c)
&nbsp;Convertible into the common stock of the Company at the option of the holder at a 50% discount from the average of the lowest
three Trading Prices &nbsp;for the common stock during the 10 trading day period ending one Trading Day prior to the date the conversion
notice is sent by the holder. &quot;Trading Price&quot; means the closing bid price on the applicable trading market as reported
by a reliable reporting service.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On February 28, 2012
the Company amended the terms of &nbsp;$85,500 in existing principal indebtedness as well as 3,710 &nbsp;of interest accrued but
unpaid to be as follows:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The aggregate indebtedness
of $89,210 shall bear simple interest, be payable upon demand of the holder, and be convertible into the common shares of the company
at a conversion price per share equal to 60% (the &ldquo;Discount&rdquo;) of the lowest closing bid price for the Company&rsquo;s
common stock during the 5 trading days immediately preceding a conversion date, as reported by Bloomberg. provided that if the
closing bid price for the common stock on the date in which the conversion shares are deposited into Holder&rsquo;s brokerage account
and confirmation has been received that Holder may execute trades of the conversion shares ( Clearing Date) is lower than the Closing
Bid Price, then the purchase price for the conversion shares shall be adjusted such that the Discount shall be taken from the closing
bid price on the Clearing Date, and the Company shall issue additional shares to Purchaser to reflect such adjusted Purchase Price
(&ldquo;Bonus Shares&rdquo;). The company has agreed on a limitation on conversion equal to 9.99% of the Company&rsquo;s outstanding
common stock. </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 16, 2012 the&nbsp;<FONT STYLE="background-color: white">Company
issued a convertible promissory note in the amount of $42,500 which was received April 21, 2012. The note bears an interest rate
of eight percent (8%), matures on January 18, 2013. and may be converted after 180 days from execution of this note for shares
of the Company&rsquo;s common stock. The note may be converted at a fifty two percent (52%) discount to the average of the lowest
3 closing bid prices of the common stock during the 10 trading days prior to the conversion date. </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The securities were issued pursuant to Section 4(2)
of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The securities
were sold directly through our management. No commission or other consideration was paid in connection with the sale of the securities.
There was no advertisement or general solicitation made in connection with this Offer and Sale of securities.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The note contained a provision that until such time as the
shares of common stock issuable upon conversion of the Note have been registered under the Act or otherwise may be sold pursuant
to Rule 144 without any restriction as to the number of securities as of a particular date that can then be immediately sold,
each certificate for shares of common stock issuable upon conversion of the note &nbsp;that has not been so included in an effective
registration statement or that has not been sold pursuant to an effective registration statement or an exemption that permits
removal of the legend, shall bear a restrictive legend.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On June 15, 2012 the
Company amended the terms of $102,349 in existing principal indebtedness as follows:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The Aggregate Indebtedness
of $102,349 is convertible at Holder&rsquo;s option at a conversion price per share equal to 60% (the &ldquo;Discount&rdquo;) of
the lowest closing bid price for the Company&rsquo;s common stock during the 5 trading days immediately preceding a conversion
date, as reported by Bloomberg (the &ldquo;Closing Bid Price&rdquo;); provided that if the closing bid price for the common stock
on the date in which the conversion shares are deposited into Holder&rsquo;s brokerage account and confirmation has been received
that Holder may execute trades of the conversion shares ( Clearing Date) is lower than the Closing Bid Price, then the purchase
price for the conversion shares shall be adjusted such that the Discount shall be taken from the closing bid price on the Clearing
Date, and the Company shall issue additional shares to Purchaser to reflect such adjusted Purchase Price (&ldquo;Bonus Shares&rdquo;).
The company has agreed on a limitation on conversion equal to 9.99% of the Company&rsquo;s outstanding common stock. </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On July 26, 2012, the Company issued a convertible note in
the principal amount of $63,000 to Asher Enterprises, Inc. The Note bears interest at the rate of 8% per annum and matures on April
30, 2013. The Note is convertible any time during the period beginning on the date which is one hundred eighty (180) days following
the date of the Note into common stock of the Company, at Asher&rsquo;s option, at a 39% discount to the average of the three lowest
closing bid prices of the common stock during the 10 Trading Day period prior to conversion as Trading Day is defined in the Note.<FONT STYLE="background-color: white">
</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The securities were issued pursuant to Section 4(2)
of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The securities
were sold directly through our management. No commission or other consideration was paid in connection with the sale of the securities.
There was no advertisement or general solicitation made in connection with this Offer and Sale of securities.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The note contained a provision that until such time as the shares
of common stock issuable upon conversion of the Note have been registered under the Act or otherwise may be sold pursuant to Rule
144 without any restriction as to the number of securities as of a particular date that can then be immediately sold, each certificate
for shares of common stock issuable upon conversion of the note &nbsp;that has not been so included in an effective registration
statement or that has not been sold pursuant to an effective registration statement or an exemption that permits removal of the
legend, shall bear a restrictive legend.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On August 21, 2012 the <FONT STYLE="background-color: white">Company
amended the terms of $59,000 in existing principal indebtedness as follows:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The Aggregate Indebtedness
of $59,000 is convertible at Holder&rsquo;s option at a conversion price per share equal to 60% (the &ldquo;Discount&rdquo;) of
the lowest closing bid price for the Company&rsquo;s common stock during the 10 trading days immediately preceding a conversion
date, as reported by Bloomberg (the &ldquo;Closing Bid Price&rdquo;); provided that if the closing bid price for the common stock
on the date in which the conversion shares are deposited into Holder&rsquo;s brokerage account and confirmation has been received
that Holder may execute trades of the conversion shares ( Clearing Date) is lower than the Closing Bid Price, then the purchase
price for the conversion shares shall be adjusted such that the Discount shall be taken from the closing bid price on the Clearing
Date, and the Company shall issue additional shares to Purchaser to reflect such adjusted Purchase Price (&ldquo;Bonus Shares&rdquo;).
The company has agreed on a limitation on conversion equal to 9.99% of the Company&rsquo;s outstanding common stock</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On September 20, 2012 the&nbsp;<FONT STYLE="background-color: white">Company
issued a convertible promissory note in the amount of $63,000 cash from which was received September 27, 2012. The note bears an
interest rate of eight percent (8%), matures on June 25, 2013. and may be converted after 180 days from execution of this note
for shares of the Company&rsquo;s common stock. The note may be converted at a thirty nine percent (39%) discount to the average
of the lowest 3 closing bid prices of the common stock during the 10 trading days prior to the conversion date. </FONT></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The securities were issued pursuant to Section 4(2)
of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The securities
were sold directly through our management. No commission or other consideration was paid in connection with the sale of the securities.
There was no advertisement or general solicitation made in connection with this Offer and Sale of securities.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The note contained a provision that until such time as the shares
of common stock issuable upon conversion of the Note have been registered under the Act or otherwise may be sold pursuant to Rule
144 without any restriction as to the number of securities as of a particular date that can then be immediately sold, each certificate
for shares of common stock issuable upon conversion of the note &nbsp;that has not been so included in an effective registration
statement or that has not been sold pursuant to an effective registration statement or an exemption that permits removal of the
legend, shall bear a restrictive legend.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Use of Proceeds, Registered Offering</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Company has filed a registration statement on Form S-1
under the Securities Act of 1933 registering for resale up to 37,640,314 shares of our common stock by Southridge which are Put
Shares that may be put to Southridge pursuant to an Equity Purchase Agreement dated as of June 1, 2012 by and between Southridge
and the Company (&ldquo;June Purchase Agreement&rdquo;). The Registration Statement was declared effective by the United States
Securities and Exchange Commission on August 27, 2012.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The June Purchase Agreement with Southridge provides that
Southridge is committed to purchase up to $10 million of our common stock. We may draw on the facility from time to time, as and
when we determine appropriate in accordance with the terms and conditions of the June Purchase Agreement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">We will not receive any proceeds from the sale of the common
stock offered through this prospectus by Southridge. However, we will receive proceeds from any sale of the common stock under
the Purchase Agreement to Southridge</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Between September 4, 2012 and September 17, 2012 the Company
sold 26,802,465 common shares to Southridge for the gross amount of $50,000 pursuant to the June Purchase Agreement. The proceeds
were utilized as follows:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$20,000 was utilized to pay debt due to Southridge</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$2,500 was paid to Capital Path Securities who acted as placement agent </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">$27,500 was utilized for working capital purposes</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On October 2 , 2012 the Company sold 10,837,849 common shares
to Southridge for the gross amount of $14,300 pursuant to the June Purchase Agreement. Total gross proceeds of $14,300 were utilized
to pay $14,300 of debt due to Southridge by the Company.</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 0pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Item 6. Selected Financial Data</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As we are a &ldquo;smaller reporting company&rdquo; as defined
by Rule 229.10(f)(1), we are&nbsp;not required to provide the information required by this Item.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Item 7. Management&rsquo;s Discussion and Analysis of
Financial Condition and Results of Operations</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of August 31, 2012, we had Trade Accounts Receivable of
$ 2,268 and as of August 31, 2011 we had Trade Accounts Receivable of $3,135.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The decrease in Trade Accounts Receivable of approximately
27% is attributable to successful collection of $867 of delinquent payments due from a client of the McDonald Animal Hospital.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of August 31, 2012 we had Due from an Affiliate of $39,140
and as of August 31, 2011 we had Due from an Affiliate of $0.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The increase in Due from an Affiliate is primarily attributable
to the reclassification of $59,500 of rental expenses prepaid to a shareholder of the Company to a non interest bearing liability
of the shareholder due at the demand of the Company as well as $240 in expenses paid by the Company for the benefit of the shareholder
offset by a payment made to the company during the twelve months ended August 31, 2012 of $20,600.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of August 31, 2012, we had a balance of $13,000 in Current
Portion of Prepaid Expenses compared to August 31, 2011 where the balance totaled $62,200.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The decrease in Current Portion of Prepaid Expenses of approximately
79% was primarily attributable to the reclassification of rental expenses prepaid to a shareholder of the Company to a non interest
bearing liability of the shareholder due at the demand of the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of August 31, 2012, the balance in Non-Current Portion
of Prepaid Expenses totaled $0 compared to the August 31, 2011 balance of $10,300.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The decrease in the Non-Current Portion of Prepaid Expenses
was primarily attributable to the applicable portion of Prepaid Rent being reallocated from a non-current asset to a current asset.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of August 31, 2012, we had Deposits in the amount of $1,151&nbsp;&nbsp;and
as of August 31, 2011 we had Deposits of $0..</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The decrease in Deposits of 100% is attributable to deposits
sent by the Company to San Diego Gas and Electric Company to be being applied toward utility charges incurred by the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of August 31, 2012, we had Accounts Payable of $74,574
and as of August 31, 2011 we had Accounts Payable of&nbsp;&nbsp;$27,564 .</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The increase in Accounts Payable of approximately 170 % is
primarily attributable to s primarily attributable to increases in outstanding obligations of the Company incurred in the course
of business as well as the incurring by the Company of $20,199 in payables pursuant to that agreement entered into by and between
the Company and Titterington Veterinary Services, Inc., Dr. Ronald Titterington and Dr. Kathy Snell.</P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of August 31, 2012 we had Notes Payable of $225,362 and
as of August 31, 2011 we had Notes payable of $159,911.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The increase in Notes Payable of approximately 40% is primarily
attributable to a combination of additional borrowings by the Company incurred in order to fund operations and the reclassification
of $57,500 of accrued salary to Notes Payable as a result of assignment of the rights to that payment to a third party offset by
the reclassification of approximately $280,559 of indebtedness to Convertible Notes payable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of August 31, 2012 we had Convertible Notes Payable (net
of unamortized discount resulting from a beneficial conversion feature) totaling $121,495 and as of August 31, 2011 we had Convertible
Notes Payable (net of unamortized discount resulting from a beneficial conversion feature) totaling $42,430. .</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The increase in Convertible Notes Payable (net of unamortized
discount resulting from a beneficial conversion feature) of approximately 86% is primarily attributable to:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The issuance of $456,059 in convertible debentures through
a combination of initial issuances and modifications of the terms and conditions of existing securities</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The recognition of $380,480 of interest expense attributable
to amortizations of discounts recognized</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Offset by:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 0pt; text-align: justify">$369,059 in principal amount of convertible indebtedness
converted into common stock</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 0pt; text-align: justify">$37,500 in convertible debt prepaid by the Company</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 0pt; text-align: justify">$350,915 of discounts on Convertible Notes recognized</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of August 31, 2012 we had Accrued Expenses of $119,726
and As of August 31, 2011, we had Accrued Expenses of $67, 206</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">The increase in accrued expenses of approximately 78% is
primarily attributable to:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 20pt">(a) $15,239 in net interest accrued</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 20pt">(b) $44,500 in net additions to salaries accrued but unpaid</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">offset by $7219 net reductions in accrued tax expenses</P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Material Changes in Results of Operations</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Revenues were $426,252 for the twelve months ended August
31, 2012. Revenues were $349,141 for the twelve months ended August 31, 2011. Net Losses were $1,889,563 for the twelve months
ended August 31, 2012 and $951,783 for the same period ended August 31, 2011.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The increase in Net Losses of approximately 98% is primarily
attributable to:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Increase in Cost of Revenue of $29,894 </FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Increase in rental costs of $18,216</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Increase in Consultant&rsquo;s Expenses of $268,522</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Loss on early extinguishment of Debt recognized in the amount of $18,647</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Increase in Expenses incurred pursuant to that agreement entered into by and between the Company
and Titterington Veterinary Services, Inc., Dr. Ronald Titterington and Dr. Kathy Snell.</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Impairment of intangible Assets recognized in the amount of $683,333</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Increases in Interest Expense attributable to amortization of discount in the amount of $364,052</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Expenses incurred resulting from shares issued pursuant to contractual obligations in the amount
of $23,868</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; text-align: justify"></TD><TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Expenses paid for through the issuance of Preferred shares in the amount of $75,000 such expenses
being incurred in connection with that Equity Purchase Agreement entered into by and between the Company and Southridge <FONT STYLE="color: black; background-color: white">on
February 27, 2012.</FONT></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="color: black; background-color: white">Offset
by</FONT> :</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">A decrease in Research and Development Expenses of $103,265</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">A decrease in general and Administrative Expenses of $231,185</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">An increase in other income recognized of $94,850 attributable
to cancellation of stock previously issued for services</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Recognition of $187,699 in revenue realized as a result of
that agreement entered into by and between the Company and Titterington Veterinary Services, Inc., Dr. Ronald Titterington and
Dr. Kathy Snell.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">All operating revenues realized by the Company re primarily
derived through provision of Veterinary Services by the McDonald Animal Hospital. The increases in Total Revenues for the twelve
months ended August 31,2012 as compared to the twelve months ended August 31 , 2011 is partially attributable to the fact that
the acquisition of the assets of Pet Pointers, Inc. by the Company through which the Company acquired the McDonald Animal Hospital,
had not occurred until January 4, 2011.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of August 31, 2012 we had $42,737 cash on hand and current
liabilities of $549,157 (exclusive of convertible debt discount attributable to a beneficial conversion feature) such liabilities
consisting of Accounts Payable, Notes Payable, Convertible Notes Payable, Amounts due to Affiliates / Others and Accrued Expenses.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">We feel we will not be able to satisfy its cash requirements
over the next twelve months and shall be required to seek additional financing.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">We currently plan to raise additional funds primarily by
offering securities for cash and acquiring existing veterinary clinics with the ability to generate cash flow to fund operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">There is no guarantee that we will be able to raise any capital
through any type of offerings. We can provide no assurance that we can acquire veterinary clinics which can generate sufficient
cash flow to neither fund our operations nor can any assurance be made that we can acquire one or more additional veterinary clinics
in the near future or at all. We cannot assure that we will be successful in obtaining additional financing necessary to implement
our business plan. We have not received any commitment or expression of interest from any financing source that has given us any
assurance that we will obtain the amount of additional financing in the future that we currently anticipate. For these and other
reasons, we are not able to assure that we will obtain any additional financing or, if we are successful, that we can obtain any
such financing on terms that may be reasonable in light of our current circumstances.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of January 26, 2013 we are not party to any binding agreements
which would commit Entest to any material capital expenditures.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Item 7A. Quantitative and Qualitative Disclosures About
Market Risk</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As we are a smaller reporting
company, as defined by Rule 229.10(f)(1), we are&nbsp;not required to provide the information required by this Item.</P>

<P STYLE="font: 12pt/1.5pt Times New Roman, Times, Serif; margin: 8.5pt 0 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 0pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 0pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Item 8. Financial Statements and Supplementary Data</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">FINANCIAL STATEMENTS</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 14pt Book Antiqua, Times, Serif; margin: 0">SEALE AND BEERS, CPAs</P>

<P STYLE="font: 14pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"><I><U>PCAOB &amp; CPAB REGISTERED AUDITORS</U></I></P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt">www.sealebeers.com</P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: center"><B><U>REPORT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</U></B></P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: justify"><B>To the Board of Directors and
Stockholders of</B></P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: justify"><B>Entest BioMedical Inc. </B></P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">We have audited the accompanying
balance sheets of Entest BioMedical, Inc. as of August 31, 2012, and the related statements of income, stockholders&rsquo; equity
(deficit), and cash flows for the one-year period ended August 31, 2012. Entest BioMedical, Inc.&rsquo;s management is responsible
for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits.</P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">We conducted our audits in accordance with the standards
of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required
to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration
of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances,
but not for the purpose of expressing an opinion on the effectiveness of the company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management,
as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our
opinion.</P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">In our opinion, the financial statements referred to
above present fairly, in all material respects, the financial position of Entest BioMedical, Inc. as of August 31, 2012, and the
related statements of income, stockholders&rsquo; equity (deficit), and cash flows for the year ended August 31, 2012 in conformity
with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: justify">The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in Note 4 to the financial statements, the Company has
incurred recurring losses and recurring negative cash flow from operating activities, and has an accumulated deficit which raises
substantial doubt about its ability to continue as a going concern. Management&rsquo;s plans concerning these matters are also
described in Note 4. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 16pt/115% Bradley Hand ITC; margin: 0 0 10pt; text-align: justify"><B><I>/s/ Seale and Beers, CPAs</I></B></P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: justify">Seale and Beers, CPAs</P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: justify">Las Vegas, Nevada</P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: justify">January 25, 2012</P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt"><I>&nbsp;</I></P>

<P STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; margin: 0 0 10pt; text-align: center"><I><U>50 S. Jones Blvd. Suite 202
Las Vegas, NV 89107 Phone: (888)727-8251 Fax: (888)782-2351</U></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">To: The Board of Directors
and Stockholders</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Entest BioMedical, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">I have audited the accompanying
consolidated balance sheet of Entest BioMedical, Inc. as of August 31, 2011 and 2010 and the related statements of operations,
stockholders&rsquo; equity and cash flows for the years ended August 31, 2011 and 2010, and for the period from inception (August
22, 2008) to August 31, 2011. These financial statements are the responsibility of the Company&rsquo;s management. &nbsp;My responsibility
is to express an opinion on these financial statements based on my audit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">Except as discussed in the
following paragraph, I conducted my audits in accordance with the standards of the Public Company Accounting Oversight Board (United
States). &nbsp;Those standards require that I plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. &nbsp;The Company is not required to have, nor was I engaged to perform, an audit
of its internal control over financial reporting. &nbsp;My audit included consideration of internal control over financial reporting
as a basis for designing audit procedures that are appropriate in the circumstances, but do not for the purpose of expressing an
opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting. &nbsp;Accordingly, I express no
such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.
&nbsp;An audit also includes assessing the accounting principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. &nbsp;I believe that my audit provides a reasonable basis for my opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">In my opinion, the financial
statements referred to in the first paragraph present fairly, in all material respects, the financial position of Entest BioMedical,
Inc. as of August 31, 2011 and 2010 and the results of its operations and changes in stockholders equity and cash flows for the
years ended August 31, 2011 and 2010, and the period from inception (August 22, 2008) to August 31, 2011 in conformity with accounting
principles generally accepted in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">The accompanying financial
statements have been prepared assuming that the Company is a going concern. &nbsp;As discussed in Note 4 to the financial statements,
the Company has not generated income and has accumulated losses. &nbsp;This raises substantive doubt about the Company&rsquo;s
ability to continue as a going concern. &nbsp;Management&rsquo;s plans in regard to these matters are also described in Note 8.
&nbsp;The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"><I><U>/ s /John Kinross-Kennedy</U></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">John Kinross-Kennedy</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Certified Public Accountant</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">Irvine, California</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white">October 31, 2011</FONT>&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">ENTEST
    BIOMEDICAL, INC.</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Consolidated
    Balance Sheet</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 9%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 58%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 19%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt/115% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">As
    of </FONT></TD>
    <TD NOWRAP STYLE="width: 14%; padding-right: 5.4pt; padding-left: 5.4pt; font: 8pt/115% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">As
    of</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">August
    31,</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">August
    31,</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">2012</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">2011</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">ASSETS</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Current
    Assets</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Cash</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    42,737 </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    43,901 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Trade
    accounts receivable, less allowance for uncollectable accounts</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">of
    $0 and $0 at February 29, 2012 and August 31, 2011 respectively</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">2,268
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">3,135
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Inventory</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">10,298
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">7,986
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Due
    from Affiliate</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">39,140
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">0
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Current
    Portion of Prepaid Expenses</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">13,000
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">62,200
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Employee
    Receivable</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">4,349
    </FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">4,349
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Total
    Current Assets</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">111,792
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">121,571
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Property
    &amp; Equipment (Net of Accumulated Depreciation)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">8,832
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">17,293
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Goodwill</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">405,000
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">405,000
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Intangible
    Assets (Net of Accumulated Amortization)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">1,052
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">1,828
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Non
    Current Portion of Prepaid Expenses</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">10,300
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Deposits</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">1,151
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">0
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">TOTAL
    ASSETS</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 2.25pt double; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    527,827 </FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 2.25pt double; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    555,992 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">LIABILITES
    AND STOCKHOLDERS' EQUITY</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Current
    Liabilities</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Accounts
    Payable</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    74,574 </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    27,564 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Notes
    Payable</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">225,362
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">159,911
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Convertible
    notes payable, net of discount</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">121,495
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">42,430
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Due
    to Other</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">8,000
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">8,000
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Accrued
    Expenses</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">119,726
    </FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">67,206
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 10pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Total
    Current Liabilities</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">549,157
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">305,111
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Notes
    Payable</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">36,469
    </FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">79,143
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">TOTAL
    LIABILITIES</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">585,626
    </FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">384,254
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">STOCKHOLDERS'
    EQUITY</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Common
    Stock, $0.001 par value, authorized 1,000,000,000 shares;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">issued
    and outstanding 223,492,927 shares</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">as
    of August 31, 2012 and August 31, 2011 respectively</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">223,493
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">20,838
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Preferred
    Stock , $0.001 par value 5,000,000 shares authorized,</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">0
    shares issued and outstanding as of August 31,2012 and August 31, 2011</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">0
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Series
    AA Preferred Stock, $0.001 par value 100,000 shares authorized,</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">5,000
    shares issued and outstanding at August 31, 2012 and </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">as
    of August 31, 2011</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">5
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">5
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Series
    B Preferred</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"> </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"> </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$0.001
    par value, 4,400,000 shares authorized, 3,201,397 and 0</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">issued
    and outstanding as of August 31, 2012 and August 31, 2011</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">3,201</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;0&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">NonVoting
    Convertible Preferred</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"> </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$1
    par value, 200,000 shares authorized, 75,000 and 0</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">issued
    and outstanding as of August 31, 2012 and August 31, 2011</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><FONT STYLE="font-size: 8pt">75,000&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">0
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Additional
    Paid in Capital</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">3,030,642
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">1,619,330
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Contributed
    Capital</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">274,162
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">274,162
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Accumulated
    Deficit</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(3,664,302)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(1,742,597)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Total
    Stockholders' Equity</FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(57,799)</FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">171,738
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">TOTAL
    LIABILITIES &amp; STOCKHOLDERS' EQUITY</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 2.25pt double; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    527,827 </FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 2.25pt double; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    555,992 </FONT></TD></TR>
</TABLE>



<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">The Accompanying Notes are an integral part of these Financial
Statements</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="3" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">ENTEST
    BIOMEDICAL INC.</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="3" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Consolidated
    Statement of Operations</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">For
    the </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">For
    the </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 15%"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Year
    Ended </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 15%"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Year
    Ended </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">August
    31</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">August
    31</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">2012</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">2011</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">REVENUES</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Revenues
    from Veterinary Services</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    419,336 </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    349,141 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Online
    Revenues</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">6,916
    </FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">TOTAL
    REVENUE </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">426,252
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">349,141
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Cost
    of Revenue</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">119,299
    </FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">89,405
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">GROSS
    PROFIT</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">306,953
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">259,736
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">COSTS
    AND EXPENSES</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Research
    and Development</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">5,798
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">109,063
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Rent
    Costs</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">126,812
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">108,596
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">General
    and Administrative</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">562,424
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">793,609
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Incorporation
    Costs</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Consultant's
    Expenses </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">428,040
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">159,518
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Miscellaneous
    Expenses</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Total
    Costs and Expenses</FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">1,123,074
    </FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">1,170,786
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">OPERATING
    LOSS</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(816,121)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(911,050)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">OTHER
    INCOME AND EXPENSE</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Other
    Income</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">94,949
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">99
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Loss
    on Early Extinguishment of Debt</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(18,647)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Income
    generated from revenue</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">187,699
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Share
    Agreement</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Expenses
    incurred from Revenue</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Share
    Agreement</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(145,362)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Loss
    on Impairment of intangible assets</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(683,333)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Interest
    Expense</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(29,400)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(24,404)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Interest
    Expense attributable to </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">amortization
    of discount</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(380,480)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(16,428)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Expense
    attributable to issuance</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">of
    shares pursuant to contractual obligation</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;<FONT STYLE="font-size: 8pt; color: black">(23,868)</FONT></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Expense
    attributable to issuance of</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Non
    Voting Convertible Preferred </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Shares
    in connection with Stock</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Purchase
    Agreement</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(75,000)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">TOTAL
    OTHER INCOME AND EXPENSE</FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(1,073,442)</FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(40,733)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">LOSS
    BEFORE INCOME TAXES</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(1,889,563)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(951,783)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Income
    Taxes</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">0
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">0
    </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">NET
    LOSS</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(1,889,563)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(951,783)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Beneficial
    conversion feature</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">attributable
    to issuance of NonVoting</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Preferred
    Stock</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(32,142)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">NET
    LOSS available to </FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">common
    shareholders</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 2.25pt double; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(1,921,705)</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 2.25pt double; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(951,783)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">BASIC
    AND DILUTED </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">LOSS
    PER SHARE</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    (0.02)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    (0.05)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">WEIGHTED
    AVERAGE</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">94,990,042
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">19,895,368</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">NUMBER
    OF COMMON</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">SHARES
    OUTSTANDING</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">The Accompanying Notes are an integral part of these Financial
Statements</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B></B></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="20" STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Entest BioMedical, Inc. </B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="20" STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Consolidated Statement of Stockholders' Equity </B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="20" STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>For the Fiscal Years Ended August 31, 2011 and August 31, 2012 </B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="20" STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 28%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 5%; padding-right: 5.4pt; padding-left: 5.4pt; font: bold 8pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Non Voting </B></FONT></TD>
    <TD NOWRAP STYLE="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 4%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 8%; padding-right: 5.4pt; padding-left: 5.4pt; font: bold 8pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Accumulated </B></FONT></TD>
    <TD NOWRAP STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 7%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Convertible </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Deficit </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Series AA </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Series B </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Preferred </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Additional </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Contrib- </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>during the </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP COLSPAN="3" STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Common </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Preferred </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Preferred </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Paid-in </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>uted </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Development </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Shares </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Amount </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Shares </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Amount </B></FONT></TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Shares </B></FONT></TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Amount </B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Shares </B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Amount </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Capital </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Capital </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Stage </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Total </B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Balances, August 31, 2010 </B></FONT></TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>17,553,040 </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>$ 17,553 </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>$ 537,415 </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>$ 15,104 </B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>$ (790,814)</B></FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>$ (220,742)</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Common Shares issued for Cash </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">2,217,600 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">2,217 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">215,383 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">217,600 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Common Shares issued for Debt </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">781,712 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">780 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">340,387 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">341,167 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Common Shares issued to Consultants </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">74,383 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">74 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">121,967 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">122,041 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Common Stock issued to employees </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">163,766 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">164 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">303,235 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">303,399 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Restricted Stock Awards issued to employee </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">50,000 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">50 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">(50)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Restricted Stock Award Compensation </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">expense recognized </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">10,000 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">10,000 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Discount on Convertible Debt recognized </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">88,998 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">88,998 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Increases in Contributed capital </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">259,058 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">- </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">259,058 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Preferred Stock issued for Accrued compensation </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">5,000 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">5 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">1,995 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">2,000 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">Net Loss Year ended August 31, 2011 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">(951,783)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">(951,783)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: left">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>Balances, August 31, 2011 </B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>20,840,501 </B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>$ 20,838 </B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>5,000 </B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>$ 5 </B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>$1,619,330 </B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>$274,162 </B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>$(1,742,597)</B></FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B>$171,738 </B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Common Shares issued for services </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">3,272,000 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">3,269 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">168,481 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">171,750 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Common Shares issued for intangible assets </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">2,500,000 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">2,500 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">697,500 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">700,000 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Discount on Convertible Note Recognized</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">350,915 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">350,915 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Common Shares issued for debt</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">113,695,700 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">113,695 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">261,264 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">374,959 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Cancellation of Common Shares Issued</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(90,000)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(83)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(86,687)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(86,687)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Restricted Stock Award to employees</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">77,000,000 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">77,000 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(77,000)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">0 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Restricted Stock Award to consultant</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">15,000,000 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">15,000 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(15,000)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">0 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Restricted Stock Award compensation</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Expense Recognized</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">58,491 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">58,491 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Series B Preferred Dividend paid</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">3,201,39 </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">3,201 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(3,201)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">0 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Issuance of Non Voting Convertible</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Preferred Shares</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">75,000 </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">75,000 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">75,000 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Recognition of Beneficial Conversion Feature</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">32,142 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">32,142 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Non Voting Convertible Preferred Shares</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Shares issued pursuant to Contractual Obligations</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">6,274,726 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">6,274 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">17,594 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">23,868 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Cancellation of Restricted Stock Award to Employee</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(15,000,000)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(15,000)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">6,813 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(8,187)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Net Loss Year ended August 31, 2012</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(1,889,563)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(1,890,259)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Beneficial Conversion Feature Deemed Dividend</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(32,142)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(32,142)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"><B>Balance August 31, 2012 </B></FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"><B>223,492,927 </B></FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"><B>223,493 </B></FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"><B>5,000 </B></FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"><B>5 </B></FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"><B>3,201,39 </B></FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"><B>3,201 </B></FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"><B>75,000 </B></FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"><B>75,000 </B></FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"><B>3,030,642 </B></FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"><B>274,162 </B></FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"><B>(3,664,302)</B></FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 2.25pt double; font: bold 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black"><B>(57,799)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">The Accompanying Notes are an integral part of these Financial
Statements</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B></B></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 11pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">ENTEST
    BIOMEDICAL, INC.</FONT></TD>
    <TD COLSPAN="5" STYLE="padding-bottom: 10pt; font: 11pt/115% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR>
    <TD NOWRAP STYLE="vertical-align: bottom; font: 11pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: black">Consolidated
    Statement of Cash Flows</FONT></TD>
    <TD COLSPAN="5" STYLE="padding-bottom: 10pt; font: 11pt/115% Calibri, Helvetica, Sans-Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">For
    the</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">For
    the</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Year
    ended</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Year
    ended</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">August
    31</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">August
    31</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">2012</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">2011</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">OPERATING
    ACTIVITIES</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Net
    (loss)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    (1,889,563)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    (951,783)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Adjustments
    to reconcile net loss to net cash used</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">by
    operating </FONT> <FONT STYLE="font-size: 8pt; color: black">activities:</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Depreciation
    Expense</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">8,461
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">5,591
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Amortization
    Expense</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">776
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">505
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Stock
    issued as Compensation to Employees</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">48,681
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">55,399
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Stock
    issued as Compensation to Consultants </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">181,540
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">122,007
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Change
    in </FONT> <FONT STYLE="font-size: 8pt; color: black">operating assets and liabilities:</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(Increase)
    Decrease in Trade Accounts Receivable</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">867
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(3,135)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(Increase)
    Decrease in Inventory</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(2,312)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(7,986)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(Increase)
    Decrease in Employee Receivable</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(2,953)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Increase
    (Decrease) in Accounts Payable</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">47,010
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">6,222
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(Increase)Decrease
    in Due to Other</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(Increase)
    Decrease in Prepaid Expenses</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">59,500
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">10,100
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(Increase)
    Decrease in Due from Affiliate</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(39,140)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(Increase)
    Decrease in Deposits</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(1,151)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">1,059
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Increase(Decrease)
    in amortization of intangibles</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">16,667
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Increase
    (Decrease) in Accrued Expenses</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">52,520
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(60,889)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(Increase)Decrease
    on gain realized on cancellation</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">of
    stock</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(94,937)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Increase(Decrease)
    in Loss on Impairment</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">of
    Intangible Assets</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">683,333
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Net
    Cash Provided Used in Operating Activities</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(927,748)</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(825,863)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">INVESTING
    ACTIVITIES</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Purchase/Sale
    of Equipment</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">0
    </FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(22,884)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Net
    cash Provided by (Used in) Investing Activities</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">0
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; border-bottom: Black 1pt solid"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(22,884)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">FINANCING
    ACTIVITIES</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(Increase)
    Decrease in Goodwill from acquisition</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(195,000)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Stock
    issued in Payment of Debt</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Increase
    (Decrease) in Common stock issued for cash</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">217,600
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(Increase)
    Decrease in Intangible Assets (net)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(2,299)</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Increase
    (Decrease) in Common stock issued </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">for
    expenses</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">104,768
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Increase
    (Decrease) in Due to Affiliate</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">8,000
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Increase
    (Decrease) in Due to Shareholder</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Increase
    (Decrease) in Notes Payable</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">470,901
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">516,085
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Increase
    (Decrease) in Contributed Capital</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">259,058
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Increase
    (Decrease) in Additional paid in Capital</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">350,915
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">88,998
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 30pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Net
    Cash Provided by Financing Activities</FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">926,584
    </FONT></TD>
    <TD NOWRAP STYLE="border-top: windowtext 1pt solid; border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">892,442
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Net
    Increase in Cash</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">(1,164)</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">43,695
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Cash
    at Beginning of Period</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">43,901
    </FONT></TD>
    <TD NOWRAP STYLE="border-bottom: windowtext 1pt solid; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">206
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Cash
    at End of Period</FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 3px double; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    42,737 </FONT></TD>
    <TD NOWRAP STYLE="border-bottom: Black 3px double; font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$
    43,901 </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Supplemental
    Disclosure of Noncash investing and financing activities:</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; vertical-align: middle"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">12
    Months ended August 31, 2012</FONT></TD>
    <TD NOWRAP COLSPAN="2" STYLE="font: 8pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; vertical-align: middle"><FONT STYLE="font-size: 8pt; color: black">12 Months ended August 31, 2011</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Stock
    issued in payment of Debt</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$369,059
    </FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$391,167
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Stock
    issued in Acquisition of McDonald Animal Hospital</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$210,000
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">Stock
    issued pursuant to Titterington Agreement</FONT></TD>
    <TD NOWRAP STYLE="font: 8pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 8pt Times New Roman, Times, Serif; color: black">$700,000
    </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="3" STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">The Accompanying Notes are an integral part of these Financial
Statements</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="background-color: white"><B>Entest
BioMedical, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="background-color: white"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="background-color: white"><B>As
of August 31, 2012</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white"><B>NOTE 1. &nbsp;ORGANIZATION
AND DESCRIPTION OF BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Entest BioMedical Inc. (the
&ldquo;Company&rdquo;) was incorporated in the State of Nevada on September 24, 2008 as JB Clothing Corporation. &nbsp;Until July
10, 2009, the Company&rsquo;s principal business objective was the offering of active/leisure fashion design clothing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On July 10, 2009 the Company
abandoned its efforts in the field of active/leisure fashion design clothing when it acquired 100% of the share capital of Entest
BioMedical, Inc., a California corporation, (&ldquo;Entest CA&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The Company&rsquo;s current
business consists of the development and commercialization of immunotherapeutic therapies for the veterinary market as well as
the acquisition and operation of veterinary hospitals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white"><B>NOTE 2. &nbsp;SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">A. BASIS OF ACCOUNTING</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 10pt; color: black; background-color: white">The
financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under
this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company
has adopted an August 31 fiscal &nbsp;year-end.</FONT> <FONT STYLE="font-size: 10pt; color: black; background-color: white">The
Company recognizes revenue from services and product sales when the following four revenue recognition criteria are met: persuasive
evidence of an arrangement exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable,
and collectability is reasonably assured. Product sales and service revenues are recorded when the products are delivered and title
passes to customers. The customer&rsquo;s credit card is authorized and charged, or checks/cash are received at the time the services
are rendered, thereby providing reasonable assurance of collectability. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">B. PRINCIPLES OF CONSOLIDATION</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The consolidated financial
statements include the accounts of &nbsp;Entest CA, the Company&rsquo;s wholly owned subsidiary. Significant inter-company transactions
have been eliminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">C. USE OF ESTIMATES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The preparation of financial
statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those
estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">D. CASH EQUIVALENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The Company considers all
highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">E. PROPERTY AND EQUIPMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Property and equipment are
recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Property and equipment consist of
Office Equipment, medical Equipment and Computer Equipment. Expenditures that enhance the value of property and equipment are capitalized.
All property and equipment is depreciated utilizing the Straight Line Method for a period of thirty months , such period being
estimated by the Company to represent the useful life of the assets. For the Fiscal Year ended August 31, 2012 the Company incurred
depreciation expense of $8,461 and for the Fiscal Year ended August 31, 2011 the Company incurred depreciation expense of $5,591.
No depreciation has been recognized in connection with one piece of computer equipment which has yet to be put into service.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP COLSPAN="3" STYLE="font: 11pt/115% Calibri, Helvetica, Sans-Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="color: black">Property Plant and Equipment</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 43%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 11%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Acquisition Cost</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="4" STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Estimated useful Life (Months)</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Total</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Office Equipment</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">30</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">3,235 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP COLSPAN="2" STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Medical Equipment</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">30</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">17,523 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="2" STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Computer Equipment</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">30</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">2,126 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Subtotal</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">22,884 </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP COLSPAN="3" STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Less Accumulated Depreciation</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">(14,052)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Total</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">8,832 </FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">F. FAIR VALUE OF FINANCIAL
INSTRUMENTS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Fair value is the price that
would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous
market in an orderly transaction between market participants on the measurement date. &nbsp;A fair value hierarchy requires an
entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required
by the standard that the Company uses to measure fair value:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Level 1: &nbsp;Quoted prices
in active markets for identical assets or liabilities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Level 2: &nbsp;Observable
inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; &nbsp;quoted prices in markets that
are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full
term of the related assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Level 3: &nbsp;Unobservable
inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The Company&rsquo;s financial
instruments as of August 31, 2012 consisted of $261,831, of Notes Payable, $121,495 of Convertible Notes payable (net of discount),
$8,000 due to TheraCyte, Inc, $4,349 of Employee Receivables and $39,140 due from an affiliate. The fair value of all of the Company&rsquo;s
financial instruments as of September 30, 2012 were valued according to the Level 3 input. The carrying amount &nbsp;of the financial
instruments is equal to the fair value as determined by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Company has determined that there are no Level 1 or Level 2
inputs for determining the fair value of the Company&rsquo;s financial instruments. Fair value was determined by the Company utilizing
its own assumptions and estimation. There were no transfers between levels for the period presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">G. INCOME TAXES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The Company accounts for income
taxes using the liability method prescribed by ASC 740, &ldquo;<I>Income Taxes.</I>&rdquo; Under this method, deferred tax assets
and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities
using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records
a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that
some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is
recognized as income or loss in the period that includes the enactment date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The Company applied the provisions
of ASC 740-10-50, &ldquo;Accounting For Uncertainty In Income Taxes&rdquo;, which provides clarification related to the process
associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review
until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given
audit period could result in an adjustment to the Company&rsquo;s liability for income taxes. Any such adjustment could be material
to the Company&rsquo;s results of operations for any given quarterly or annual period based, in part, upon the results of operations
for the given period. As of August 31, 2011 and 2010, the Company had no uncertain tax positions, and will continue to evaluate
for uncertain positions in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The Company generated a deferred
tax credit through net operating loss carry forward. &nbsp;However, a valuation allowance of 100% has been established.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Interest and penalties on
tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic
740-10-50-19.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">H. &nbsp;BASIC EARNINGS (LOSS)
PER SHARE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;The Financial Accounting
Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, &quot;Earnings Per Share&quot;, which specifies the
computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock.
ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted
the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by
the weighted average number of common shares outstanding. All convertible debt has an anti-dilutive effect on the EPS , therefore
Diluted earnings per share are the same as basic earnings per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white"><B>NOTE 3. &nbsp;RECENT ACCOUNTING
PRONOUNCEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On May 2011, the Financial Accounting Standards Board (FASB) issued
Accounting Standards Update (ASU) No. 2011-04, &quot;Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements
in U.S. GAAP and IFRSs.&quot; The amendments in this update generally represent clarifications of Topic 820, but also include some
instances where a particular principle or requirement for measuring fair value or disclosing information about fair value measurements
has changed. This update results in common principles and requirements for measuring fair value and for disclosing information
about fair value measurements in accordance with U.S. GAAP and IFRS. The amendments in this update are to be applied prospectively.
The amendments are effective for interim and annual periods beginning after December 15, 2011. Early application is not permitted.
The Company does not expect this guidance to have a significant impact on its consolidated financial position, results of operations
or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">In June 2011, the FASB issued ASU No. 2011-05, &quot;Presentation
of Comprehensive Income.&quot; This update was amended in December 2011 by ASU No. 2011-12, &quot;Deferral of the Effective Date
for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards
Update No. 2011-05.&quot; This update defers only those changes in update 2011-05 that relate to the presentation of reclassification
adjustments. All other requirements in update 2011-05 are not affected by this update, including the requirement to report comprehensive
income either in a single continuous financial statement or in two separate but consecutive financial statements. ASU No. 2011-05
and 2011-12 are effective for fiscal years (including interim periods) beginning after December 15, 2011. The Company does not
expect this guidance to have a significant impact on its consolidated financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">In December 2011, the FASB issued ASU No. 2011-11, &quot;Disclosures
about Offsetting Assets and Liabilities.&quot; The amendments in this update require enhanced disclosures around financial instruments
and derivative instruments that are either (1) offset in accordance with either ASC 210-20-45 or ASC 815-10-45 or (2) subject to
an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either
ASC 210-20-45 or ASC 815-10-45. An entity should provide the disclosures required by those amendments retrospectively for all comparative
periods presented. The amendments are effective during interim and annual periods beginning on or after January 1, 2013. The Company
does not expect this guidance to have any impact on its consolidated financial position, results of operations or cash flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">A variety of proposed or otherwise potential accounting standards
are currently under study by standard setting organizations and various regulatory agencies. &nbsp;Due to the tentative and preliminary
nature of those proposed standards, the Company&rsquo;s management has not determined whether implementation of such standards
would be material to its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>NOTE 4. &nbsp;GOING CONCERN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The accompanying financial
statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $3,664,302
during the period from August 22, 2008 (inception) through August 31, 2012. This condition raises substantial doubt about the Company's
ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations,
to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Management plans to raise
additional funds primarily by offering securities for cash. Management has raised $197,500 net of legal expenses in the twelve
months ended August 31, 2012 through the issuance of convertible notes. The Company has also raised $261,475 from other borrowings
during the twelve month ended August 31, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On June 1, 2012 the Company entered into an Equity Purchase Agreement
(the &quot;June Purchase Agreement&quot;) with Southridge Partners II, LP, a Delaware limited partnership (&quot;Southridge&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Under the terms of the June Purchase Agreement, Southridge will
purchase, at the Company's election, up to $10,000,000 of the Company's registered common stock (the &quot;Shares&quot;). During
the term of the Purchase Agreement, the Company may at any time deliver a &quot;put notice&quot; to Southridge thereby requiring
Southridge to purchase a certain dollar amount of the Shares. Simultaneous with the delivery of such Shares, Southridge shall deliver
payment for the Shares. Subject to certain restrictions, the purchase price for the Shares shall be equal to 91% of the average
of the two lowest Closing Prices during the Valuation Period as such capitalized terms are defined in the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The number of Shares sold to Southridge shall not exceed the number
of such shares that, when aggregated with all other shares of common stock of the Company then beneficially owned by Southridge,
would result in Southridge owning more than 9.99% of all of the Company's common stock then outstanding. Additionally, Southridge
may not execute any short sales of the Company's common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Any sale of Shares pursuant to the June Agreement is subject to
a Registration Statement filed under the Securities Act of 1933 remaining effective for the sale by Southridge of those Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">June Agreement shall terminate (i) on the date on which Southridge
shall have purchased Shares pursuant to this Agreement for an aggregate Purchase Price of $10,000,000, or (ii) on the date occurring
24 months from the date on which the June Agreement was executed and delivered by the Company and Southridge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Company has also agreed to pay the following to Capital Path
Securities LLC for acting as the Company&rsquo;s exclusive advisor and placement agent in connection with the June Purchase Agreement
a &nbsp;cash placement fee of 5% of funds received by the Company through the sale of Shares to Southridge as such funds are received
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On June 12, 2012 a registration statement on form S-1 was filed
with the United States Securities and Exchange Commission registering 46,238,705 shares of the Company&rsquo;s &nbsp;&nbsp;common
stock that will be put to Southridge pursuant to the June Agreement which was declared effective by the United States Securities
and Exchange Commission on August 27, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">There is no guarantee that
the Company will be able to raise additional capital through offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white"><B>NOTE 5. &nbsp;NOTES
PAYABLE</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">As of August 31, 2012</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 65%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 79%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Current :</P></TD>
    <TD NOWRAP STYLE="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Bio Technology Partners Business Trust</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">13500</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Venture Bridge Advisors, Inc.</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">32508</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Southridge Partners II LLP</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">40000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Sherman Family Trust </FONT></TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">79000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Officer Loans (Note 6)</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">30,180</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Current portion of amounts to be paid on</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">behalf of Gregory McDonald and Pet Pointers, Inc. (Note 10 &nbsp;)</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">30174</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">8% Convertible Notes (Note14 )</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">105,500</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">10% Convertible Note (Note 14) </FONT></TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">59000</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Total:</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">389862</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Long Term:</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Long Term portion of amounts to be paid on</FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">behalf of Gregory McDonald and </FONT></TD>
    <TD NOWRAP STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Pet Pointers, Inc. (Note 10 &nbsp;)</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">36469</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">Total:</FONT></TD>
    <TD NOWRAP STYLE="font: 10pt/115% Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black">36469</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Both of Bio Technology
Partners Business Trust and Venture Bridge Advisors have provided lines of credit to the Company in the amount of $200,000 each
or so much thereof as may be disbursed to, or for the benefit of the Company by Lender in Lender's sole and absolute discretion.</FONT>&nbsp;<FONT STYLE="background-color: white">The
unpaid principal of these lines of credit bear simple interest at the rate of ten percent per annum. Interest is calculated based
on the principal balance as may be adjusted from time to time to reflect additional advances or payments made hereunder. Principal
balance and accrued interest shall become due and payable in whole or in part at the demand of the Lender. The Sherman Family Trust
has provided a line of credit to the Company in the amount of $____ or so much thereof as may be disbursed to, or for the benefit
of the Company by Lender in Lender's sole and absolute discretion. The unpaid principal of this line of credit bears simple interest
at the rate of ten percent per annum. Interest is calculated based on the principal balance as may be adjusted from time to time
to reflect additional advances or payments made hereunder. Principal balance and accrued interest shall become due and payable
in whole or in part at the demand of the Lender. $40,000 loaned to the Company by </FONT>Southridge Partners II LLP bears no stated
interest rate and is payable at the demand of Southridge Partners II LLP.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;<B>NOTE 6. &nbsp;RELATED PARTY TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">During the quarter ended November 30, 2011 David Koos made loans
to the Company totaling $8,400. These loans are due and payable at the demand of David&nbsp; Koos and bear simple interest at a
rate of 15% per annum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">During the quarter ended February 29, 2012 David Koos made loans
to the Company totaling $7,550. These loans are due and payable at the demand of David&nbsp; Koos and bear simple interest at a
rate of 15% per annum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">During the quarter ended February 29, 2012 David Koos granted to
the Sherman Family Trust, an irrevocable trust for the benefit of Blossom Sherman, all rights to and interest in $25,956 in unpaid
indebtedness owed by the Company (bearing simple interest at a rate of 15% per annum and due and payable at the demand of the holder)
as well as $3,051 in unpaid interest owed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">During the quarter ended May 31, 2012 David Koos made loans to the
Company in the amount of&nbsp; $13,625. These loans are due and payable at the demand of David&nbsp; Koos and bear simple interest
at a rate of 15% per annum</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">As of August 31, 2012 the
Company remains indebted to David R. Koos in the principal amount of $30,180 </FONT>due and payable at the demand of David&nbsp;
Koos and bearing simple interest at a rate of 15% per annum</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of August 31 , 2012 Bio-Matrix Scientific Group, Inc.
(&ldquo;BMSN&rdquo;) , a major shareholder of the Company, is indebted to the Company in the amount of $39,140. This amount is
non interest bearing and is due at the demand of the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white"><B>NOTE 7. &nbsp;INCOME
TAXES</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR>
    <TD STYLE="font: 1pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 17px; font: 1pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 159px; font: 1pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1px; font: 1pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 3px solid; font: bold 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As of August 31, 2012</B></FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 3px solid; font: 10pt/115% Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif; border-bottom: Black 3px solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Deferred tax assets:</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net operating tax carry forwards</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,250,503</FONT>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-0-</FONT>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Gross deferred tax assets</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,250,503&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Valuation allowance</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1,250,503)</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net deferred tax assets</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 2.25pt double; font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-0-&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">As of &nbsp;August
31 ,2012 &nbsp;the Company has a Deferred Tax Asset of $1,250,503 completely attributable to net operating loss carry forwards
of approximately $3,677,949 &nbsp;(which expire 20 years from the date the loss was incurred) consisting of:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify">(a) $ 13,647 of Net Operating
Loss carry forwards acquired in the reverse acquisition of Entest BioMedical, Inc., a California corporation, and</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 40pt; text-align: justify">(b) $ 3,664,302
&nbsp;of Net Operating Loss carry forwards attributable to Entest BioMedical, Inc.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Realization of deferred
tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry
forwards are expected to be available to reduce taxable income. A valuation allowance is recorded when it is &ldquo;more likely-than-not&rdquo;
that a deferred tax asset will not be realized. In addition, the reverse acquisition in which Entest BioMedical, Inc. was involved
in 2009 has resulted in a change of control. &nbsp;Internal Revenue Code Sec 382 limits the amount of income that may be offset
by net operating loss (NOL) carryovers after an ownership change. As a result, the Company has recorded a valuation allowance reducing
all deferred tax assets to $ -0-.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Income tax is calculated
at the 34% Federal Corporate Rate.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white"><B>NOTE 8. &nbsp;ACQUISITION
OF ENTEST CA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On July 10, 2009 the Company
acquired 100% of Entest CA, a California corporation and wholly owned subsidiary of the Company, from BMSN for consideration consisting
of (a) the issuance to BMSN of 10,000,000 newly issued common shares of Entest and (b) the return by Mr. Rick Plote of 10,000,000
shares of Entest&rsquo;s common stock previously issued to him by Entest for cancellation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white"><B>NOTE 9. &nbsp;ACQUISITION
OF THE ASSETS OF PET POINTERS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On January 4, 2011Entest CA
acquired from Pet Pointers, Inc., a California corporation doing business as McDonald Animal Hospital (&ldquo;Seller&rdquo;), and
Dr. Gregory McDonald DVM (&ldquo;McDonald&rdquo;) all the goodwill from McDonald and assets of Seller except cash and accounts
receivables used in connection with the operation of a veterinary medical clinic located at 225 S. Milpas Street, Santa Barbara,
CA 93103 (the &quot;Business&quot;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Consideration for the acquisition
consisted of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 20pt; text-align: justify; text-indent: 0pt"><FONT STYLE="background-color: white">&nbsp;&nbsp;&nbsp;I. $70,000
in cash</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 20pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 20pt; text-align: justify; text-indent: 0pt"><FONT STYLE="background-color: white">&nbsp;&nbsp;&nbsp;II. $210,000
of the Company&rsquo;s &nbsp;common shares valued at the closing price per share as of January 4, 2011</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 20pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 20pt; text-align: justify; text-indent: 0pt"><FONT STYLE="background-color: white">&nbsp;&nbsp;&nbsp;III. Payment
of no more than $78,000 to a creditor of the Seller to be paid in monthly installments of $1,500 per month</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 20pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 20pt; text-align: justify; text-indent: 0pt"><FONT STYLE="background-color: white">&nbsp;&nbsp;&nbsp;IV. Payment
of no more than $25,000 to additional creditors of the Seller to be paid in monthly installments of $825 per month</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 20pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 20pt; text-align: justify; text-indent: 0pt"><FONT STYLE="background-color: white">&nbsp;&nbsp;&nbsp;V. Payment
of $50,000 to McDonald on the first business day of the fourth month following the closing of the acquisition (&ldquo;Closing&rdquo;)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>NOTE 10. COMMITMENTS AND CONTINGECIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On November 1, 2011,
the Company entered into an agreement to lease approximately 2,320 square feet of office space beginning December 1, 2011 for a
period of five years.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Rent to be charged
to the Company pursuant to the lease is as follows:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">$2,996 per month for
the period beginning December 1, 2011 and ending November 30, 2012</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">$3,116 per month for
the period beginning December 1, 2012 and ending November 30, 2013</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">$3,241 per month for
the period beginning December 1, 2013 and ending November 30, 2014</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">$3,371 per month for
the period beginning December 1, 2014 and ending November 30, 2015</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">$3,506 per month for
the period beginning December 1, 2015 and ending November 30, 2016</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">This property is utilized
as office space. The Company believes that the foregoing property is adequate to meet its current needs. While it is anticipated
that the Company will require access to laboratory facilities in the future, the Company believes that access to such facilities
are available from a variety of sources.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On January 4, 2011,
as part of the asset purchase agreement with the Company and Gregory McDonald and Pet Pointers, Inc., the Company pays on behalf
of Gregory McDonald and Pet Pointers monthly rent of $7,526 to Anthony Marinelli for the terms indicated in the Gregory McDonald
/ Pet Pointers lease. &nbsp;These payments are not obligations of the Company but, are payments the Company agreed to make on behalf
of Gregory McDonald and Pet Pointers as part of the Asset Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On January 4, 2011,
as part of the asset purchase agreement with the Company and Gregory McDonald on behalf of Pet Pointers, Inc., the Company pays
on behalf of Gregory McDonald and Pet Pointers monthly payments of $1,500 to Anthony and Judi Marinelli towards the extinguishment
of a total note of $78,000. These payments are payments the Company agreed to make on behalf of Gregory McDonald and Pet Pointers.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On January 4, 2011,
as part of the asset purchase agreement with the Company and Gregory McDonald on behalf of Pet Pointers, Inc., the Company pays
on behalf of Gregory McDonald and Pet Pointers an installment agreement due to the Franchise Tax Board in the amount of $11,405
with monthly payments of $400. These payments are payments the Company agreed to make on behalf of Gregory McDonald and Pet Pointers.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On January 4, 2011,
as part of the asset purchase agreement with the Company and Gregory McDonald on behalf of Pet Pointers, Inc., the Company pays
on behalf of Gregory McDonald and Pet Pointers an installment agreement due to the Internal Revenue Service in the amount of $13,595
with monthly payments of $425. These payments are payments the Company agreed to make on behalf of Gregory McDonald and Pet Pointers.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On February 3, 2011,
a Complaint (&ldquo;Complaint&rdquo;) was filed in the U.S. District Court Middle District of the State of Pennsylvania against
the Company, the Company&rsquo;s Chairman and BMSN. by 18KT.TV LLC (&ldquo;Plaintiffs&rdquo;) seeking to recover general damages
from the Company. in excess of $125,000. The Complaint alleges breach of contract and unjust enrichment relating to an investor
relations contract executed by the Company and Craig Fischer (on behalf of 18KT.TV LLC). The Complaint also seeks similar damages
from BMSN. The Company believes that the allegations in the complaint are without merit and intends to vigorously defend its interests
in this matter. At this time, it is not possible to predict the ultimate outcome of these matters.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On May 24, 2012, a Complaint (&ldquo;Complaint&rdquo;) was
filed in the U.S. Bankruptcy Court for the District of Oregon against the Company by Titterington Veterinary Services Inc. (&ldquo;TVS&rdquo;).
The Complaint is an adversary proceeding filed by TVS arising from TVS&rsquo;s bankruptcy case currently pending in U.S. Bankruptcy
Court for the District of Oregon. The Complaint alleges Breach of Contract resulting from the Company&rsquo;s alleged failure to
pay certain expenses the Company was required to pay pursuant to an agreement with TVS, Dr. Ronald Titterington, DVM and Dr. Kathy
Snell, DVM (&ldquo;TVS Agreement&rdquo;). TVS is seeking a judgment and money award against the Company in an amount to be proven
at trial which TVS estimates in the Complaint to be up to $50,000. TVS is also seeking a judgment and order against the Company
to provide an accounting of all revenues received by the Company pursuant to the TVS Agreement, all expenses paid, unpaid, and
due and owing &nbsp;pursuant to the TVS Agreement as well as a revenue share which TVS claims is due them pursuant to the TVS Agreement.
TVS is also seeking a judgment requiring the Company to turn over a sum of money equal to expenses the Company was obligated to
pay pursuant to the TVS Agreement. TVS is also seeking attorney&rsquo;s fees and expenses. &nbsp;The Company believes that the
allegations in the complaint are without merit and intends to vigorously defend its interests in this matter. At this time, it
is not possible to predict the ultimate outcome of these matters and an outcome unfavorable to the Company may have a material
adverse effect on the Company. On September 19, 2012 the Plaintiff&rsquo;s Claim for Relief for turnover and an accounting under
11 U.S.C. &sect; 542 and the Plaintiff's Claim for Relief for attorney fees were dismissed with prejudice and , as per the claim
of breach of contract, the proceeding was transferred to the United States Bankruptcy Court for the District of Southern California
for all further proceedings.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On October 10, 2012 a Complaint(&ldquo;Complaint&rdquo;)
was filed in the Superior Court of the State of California against the Company and David Koos by Dr. Gregory McDonald, a former
employee of the Company, alleging breach of contract and breach of the covenant of good faith and dealing in connection with the
assumption of lease obligations by the Company in connection with the acquisition of the assets of Pet Pointers, Inc (&ldquo;Acquisition&rdquo;)
(Note 9) breach of contract and breach of the covenant of good faith and dealing in connection with an employment agreement enters
into with Dr. McDonald inc connection with the Acquisition, breach of contract in connection with the Acquisition purchase agreement,
breach of the covenant of good faith and dealing in connection with the Acquisition purchase agreement, implied indemnity in connection
to amounts owed by Dr. McDonald to Anthony and Judi Marinelli, the Internal Revenue Service, and the California Franchise Tax Board,
intentional misrepresentation, negligent misrepresentation , failure to pay wages and violations of Sections 2802, 203, and 2806
of the California Labor Code. The Complaint seeks judgment for nominal damages, actual damages, compensatory damages, lost wages,
compensation, expenses wage benefits and penalties pursuant to California Labor Code Sections 203 et al, 2802 and 2806, indemnification,
accrued interest, punitive damages, costs of suit and attorney&rsquo;s fees.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">There were no other
legal proceedings against the Company with respect to matters arising in the ordinary course of business. The Company is not involved
in any other litigation either as plaintiffs or defendants, and has no knowledge of any threatened or pending litigation against
the Company.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On June 1, 2012 the Company entered into an Equity Purchase
Agreement (the &quot;June Purchase Agreement&quot;) with Southridge Partners II, LP, a Delaware limited partnership (&quot;Southridge&quot;).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Under the terms of the June Purchase Agreement, Southridge
will purchase, at the Company's election, up to $10,000,000 of the Company's registered common stock (the &quot;Shares&quot;).
During the term of the Purchase Agreement, the Company may at any time deliver a &quot;put notice&quot; to Southridge thereby requiring
Southridge to purchase a certain dollar amount of the Shares. Simultaneous with the delivery of such Shares, Southridge shall deliver
payment for the Shares. Subject to certain restrictions, the purchase price for the Shares shall be equal to 91% of the average
of the two lowest Closing Prices during the Valuation Period as such capitalized terms are defined in the Agreement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The number of Shares sold to Southridge shall not exceed
the number of such shares that, when aggregated with all other shares of common stock of the Company then beneficially owned by
Southridge, would result in Southridge owning more than 9.99% of all of the Company's common stock then outstanding. Additionally,
Southridge may not execute any short sales of the Company's common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Any sale of Shares pursuant to the June Agreement is subject
to a Registration Statement filed under the Securities Act of 1933 remaining effective for the sale by Southridge of those Shares.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">June Agreement shall terminate (i) on the date on which Southridge
shall have purchased Shares pursuant to this Agreement for an aggregate Purchase Price of $10,000,000, or (ii) on the date occurring
24 months from the date on which the June Agreement was executed and delivered by the Company and Southridge.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Company has also agreed to pay the following to Capital
Path Securities LLC for acting as the Company&rsquo;s exclusive advisor and placement agent in connection with the June Purchase
Agreement a &nbsp;cash placement fee of 5% of funds received by the Company through the sale of Shares to Southridge as such funds
are received by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>NOTE 11. NON VOTING CONVERTIBLE PREFERRED STOCK</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On March 27, 2012 the company issued to Southridge 75,000
shares of its nonvoting convertible preferred stock to Southridge in accordance with the terms of an Equity Purchase Agreement
entered into by and between the Company and Southridge which was terminated at the Company&rsquo;s option on June 1, 2012 (&ldquo;February
Purchase Agreement&rdquo;).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Non Voting Convertible Preferred Stock is convertible at
the option of the holder into shares of the Company&rsquo;s common stock at a conversion price equal to seventy percent (70%) of
the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the Company of the holder&rsquo;s
intent to convert.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&ldquo;CLOSING PRICE&quot; shall mean the closing bid price
for the Company&rsquo;s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&ldquo;PRINCIPAL MARKET&quot; shall mean the principal trading
exchange or market for the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&ldquo;TRADING DAY&rdquo; shall mean a day on which the Principal
Market shall be open for business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The issuance of 75,000 shares of the Company&rsquo;s nonvoting
convertible preferred stock to Southridge resulted in recognition of a beneficial conversion feature in the amount of $32,142.Accordingly,
the Company recorded a deemed dividend on the 75,000 shares of the Company&rsquo;s nonvoting convertible preferred stock of $32,142.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>NOTE 12. DIVIDEND OF SERIES B PREFERRED SHARES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On March 6, 2012 a
dividend of 3, 201,397 shares of Series B Preferred Stock was paid to the Company&rsquo;s common shareholders of record as of February
21, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><B>NOTE 13. STOCKHOLDERS EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The stockholders' equity section
of the Company contains the following classes of capital stock as of August 31, 2012:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Common Stock:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">$0.001 par value, 1,000,000,000
shares authorized 222,791,778 shares issued and outstanding as of August 31, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Preferred Stock:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">$0.001 par value 5,000,000
shares authorized of 100,000 shares authorized is authorized as Series AA Preferred Stock , $001 par value of which 5,000 shares
are issued and outstanding &nbsp;as of &nbsp;February 29, 2012 &nbsp;and 4,400,000 is authorized as Series B Preferred Stock of
which 3, 201,397 &nbsp;shares are issued and outstanding as of August 31, 2012. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Upon any liquidation, dissolution,
or winding up of the Company, whether voluntary or involuntary (collectively, a &ldquo;Liquidation&rdquo;), before any distribution
or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series B
Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings,
an amount equal to $0.10 per share of Series B Preferred Stock (the &ldquo;Liquidation Amount&rdquo;) plus all declared and unpaid
dividends thereon, for each share of Series B Preferred Stock held by them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">If, upon any Liquidation,
the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon,
in full to all holders of Series B Preferred Stock, then the entire net assets of the Company shall be distributed among the holders
of the Series B Preferred Stock, ratably in proportion to the full amounts to which they would otherwise be respectively entitled
and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or
both, at the election of the Board..</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">Non Voting Convertible Preferred Stock having a $1.00 par value:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">200,000 shares authorized of which 75, 000 shares are issued and
outstanding as of August 31, 2102.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Non Voting Convertible Preferred Stock shall convert at the option
of the holder into shares of the corporation&rsquo;s common stock at a conversion price equal to seventy percent (70%) of the lowest
Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder&rsquo;s intent
to convert.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&ldquo;CLOSING PRICE&quot; shall mean the closing bid price for
the corporation&rsquo;s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&ldquo;PRINCIPAL MARKET&quot; shall mean the principal trading exchange
or market for the corporation&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&ldquo;TRADING DAY&rdquo; shall mean a day on which the Principal
Market shall be open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>NOTE 14. &nbsp;CONVERTIBLE DEBENTURES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On May 20, 2011, the
Company issued a convertible promissory note in the amount of $42,500 which was received May 26, 2011. The note bears an interest
rate of eight percent (8%), matures on February 23, 2012 and may be converted after 180 days from execution of this note for shares
of the Company&rsquo;s common stock. The note may be converted at a forty two percent (42%) discount to the average of the lowest
3 closing bid prices of the common stock during the 10 trading days prior to the conversion date. The issuance of the note amounted
in a beneficial conversion feature of $16,398 which has been amortized under the Interest Method. $42,500 of the principal amount
due and $1700 in accrued interest has been converted into 1,012,425 shares of the common stock of the Company.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On July 5, 2011, the
Company issued a convertible promissory note (the &ldquo;Second Note&rdquo;) in the principal amount of $37,500. The Second Note,
which matures April 11, 2012, bears interest at the rate of 8% per annum. At any time after 180 days from the execution of the
Second Note, the Second Note is convertible into shares of the Company&rsquo;s common stock at the election of Asher at a conversion
price equal to a 45% discount to the average of the 3 closing bid prices of the common stock during the 10 trading day period prior
to conversion. The issuance of the note amounted in a beneficial conversion feature of $37,500 which is amortized under the Interest
Method. $37,500 of the principal amount due and $1500 in accrued interest has been converted into 6,193,242 shares of the common
stock of the Company.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On August 29, 2011,
the Company issued a convertible promissory note (the &ldquo;Third Note&rdquo;) in the principal amount of $35,000. The Third
Note, which matures May 25, 2012, bears interest at the rate of 8% per annum. At any time after 180 days from the execution of
the Third Note, the Third Note is convertible into shares of the Company&rsquo;s common stock at the election of Asher at a conversion
price equal to a 45% discount to the average of the 3 closing bid prices of the common stock during the 10 trading day period prior
to conversion. The issuance of the note amounted in a beneficial conversion feature of $35,000 which is amortized under the Interest
Method. . $35,000 of the principal amount due and $1400 in accrued interest has been converted into 21,708,333 shares of the common
stock of the Company.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black; background-color: white">On
October 25, 2011, the Company issued a convertible promissory note in the amount of $32,500. The note bears an interest rate
of eight percent (8%), matures on July 27, 2012 and may be converted after 180 days from execution of this note for shares of
the Company&rsquo;s common stock. The note may be converted at a fifty two percent (52%) discount to the average of the
lowest 3 closing bid prices of the common stock during the 10 trading days prior to the conversion date. The issuance of the
note amounted in a beneficial conversion feature of $7,634 which is amortized under the Interest Method.</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: black; background-color: white">$32,500
of the principal amount due and $1300 in accrued interest has been converted into 24,635,165 shares of the common stock of the
Company.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On December 19, 2011,
the Company issued a convertible promissory note in the amount of $37,500. The note bears an interest rate of eight percent (8%),
matures on September 21, 2012 and may be converted after 180 days from execution of this note for shares of the Company&rsquo;s
common stock. The note may be converted at a fifty two percent (52%) discount to the average of the lowest 3 closing bid prices
of the common stock during the 10 trading days prior to the conversion date. The issuance of the note amounted in a beneficial
conversion feature of $37,500 which is amortized under the Interest Method. The principal balance and $1,500 in accrued interest
was satisfied by a payment of $57,647. </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">On December 20, 2011
the Company amended the terms of $30,000 in existing debt as follows:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 60pt; text-indent: -20pt; text-align: justify"><FONT STYLE="background-color: white">(a)
&nbsp;Due and payable December 31, 2012</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 60pt; text-indent: -20pt; text-align: justify"><FONT STYLE="background-color: white">(b)
&nbsp;Simple interest of 10% from December 20, 2011 to the date the debt is fully converted or paid in full</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt 60pt; text-indent: -20pt; text-align: justify"><FONT STYLE="background-color: white">(c)
&nbsp;Convertible into the common stock of the Company at the option of the holder at a 50% discount from the average of the lowest
three Trading Prices &nbsp;for the common stock during the 10 trading day period ending one Trading Day prior to the date the conversion
notice is sent by the holder. &quot;Trading Price&quot; means the closing bid price on the applicable trading market as reported
by a reliable reporting service.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The amendment of the
note amounted in a beneficial conversion feature of $16,153 which was fully amortized by February 29, 2012. The entire principal
balance of the convertible note was converted into 1,249,975 shares of the common stock of the Company prior to February 29, 2012.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On February 28, 2012
the Company amended the terms of &nbsp;$85,500 in existing principal indebtedness as well as 3,710 &nbsp;of interest accrued but
unpaid to be as follows:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The aggregate indebtedness
of $89,210 shall bear simple interest, be payable upon demand of the holder, and be convertible into the common shares of the company
at a conversion price per share equal to 60% (the &ldquo;Discount&rdquo;) of the lowest closing bid price for the Company&rsquo;s
common stock during the 5 trading days immediately preceding a conversion date, as reported by Bloomberg. provided that if the
closing bid price for the common stock on the date in which the conversion shares are deposited into Holder&rsquo;s brokerage account
and confirmation has been received that Holder may execute trades of the conversion shares ( Clearing Date) is lower than the Closing
Bid Price, then the purchase price for the conversion shares shall be adjusted such that the Discount shall be taken from the closing
bid price on the Clearing Date, and the Company shall issue additional shares to Purchaser to reflect such adjusted Purchase Price
(&ldquo;Bonus Shares&rdquo;). The company has agreed on a limitation on conversion equal to 9.99% of the Company&rsquo;s outstanding
common stock. The amendment of the note amounted in a beneficial conversion feature of $59,473 which was fully amortized by February
29, 2012. This aggregate indebtedness was converted into 21,307,702 of the company&rsquo;s common shares.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On April 16, 2012 the&nbsp;<FONT STYLE="background-color: white">Company
issued a convertible promissory note in the amount of $42,500 which was received April 21, 2012. The note bears an interest rate
of eight percent (8%), matures on January 18, 2013. and may be converted after 180 days from execution of this note for shares
of the Company&rsquo;s common stock. The note may be converted at a fifty two percent (52%) discount to the average of the lowest
3 closing bid prices of the common stock during the 10 trading days prior to the conversion date. The issuance of the note amounted
in a beneficial conversion feature of $11,805 which is amortized under the Interest Method.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On June 15, 2012 the
Company amended the terms of $102,349 in existing principal indebtedness as follows:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The Aggregate Indebtedness
of $102,349 is convertible at Holder&rsquo;s option at a conversion price per share equal to 60% (the &ldquo;Discount&rdquo;) of
the lowest closing bid price for the Company&rsquo;s common stock during the 5 trading days immediately preceding a conversion
date, as reported by Bloomberg (the &ldquo;Closing Bid Price&rdquo;); provided that if the closing bid price for the common stock
on the date in which the conversion shares are deposited into Holder&rsquo;s brokerage account and confirmation has been received
that Holder may execute trades of the conversion shares ( Clearing Date) is lower than the Closing Bid Price, then the purchase
price for the conversion shares shall be adjusted such that the Discount shall be taken from the closing bid price on the Clearing
Date, and the Company shall issue additional shares to Purchaser to reflect such adjusted Purchase Price (&ldquo;Bonus Shares&rdquo;).
The company has agreed on a limitation on conversion equal to 9.99% of the Company&rsquo;s outstanding common stock. The issuance
of the note amounted in a beneficial conversion feature of $102,349 which is immediately amortized . This aggregate indebtedness
was converted by the Holders into 36,838,692 shares of the Company&rsquo;s common stock.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On July 26, 2012, the Company issued a convertible note in
the principal amount of $63,000 to Asher Enterprises, Inc. The Note bears interest at the rate of 8% per annum and matures on April
30, 2013. The Note is convertible any time during the period beginning on the date which is one hundred eighty (180) days following
the date of the Note into common stock of the Company, at Asher&rsquo;s option, at a 39% discount to the average of the three lowest
closing bid prices of the common stock during the 10 Trading Day period prior to conversion as Trading Day is defined in the Note.<FONT STYLE="background-color: white">
The issuance of the note amounted in a beneficial conversion feature of $63,000 which is amortized under the Interest Method.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On August 21, 2012 the <FONT STYLE="background-color: white">Company
amended the terms of $59,000 in existing principal indebtedness as follows:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">The Aggregate Indebtedness
of $59,000 is convertible at Holder&rsquo;s option at a conversion price per share equal to 60% (the &ldquo;Discount&rdquo;) of
the lowest closing bid price for the Company&rsquo;s common stock during the 10 trading days immediately preceding a conversion
date, as reported by Bloomberg (the &ldquo;Closing Bid Price&rdquo;); provided that if the closing bid price for the common stock
on the date in which the conversion shares are deposited into Holder&rsquo;s brokerage account and confirmation has been received
that Holder may execute trades of the conversion shares ( Clearing Date) is lower than the Closing Bid Price, then the purchase
price for the conversion shares shall be adjusted such that the Discount shall be taken from the closing bid price on the Clearing
Date, and the Company shall issue additional shares to Purchaser to reflect such adjusted Purchase Price (&ldquo;Bonus Shares&rdquo;).
The company has agreed on a limitation on conversion equal to 9.99% of the Company&rsquo;s outstanding common stock. The issuance
of the note amounted in a beneficial conversion feature of $53,000 which was immediately amortized . </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><B>NOTE 16. STOCK TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">During the twelve months ended August 31, 2012 the Company issued
113,695,700 Common Shares in satisfaction of $374,959 in debt and accrued interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">During the twelve months ended August 31, 2012 the Company issued
3,272,000 Common Shares for services rendered valued at $171,750.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">During the twelve months ended August 31, 2012 the Company issued
2,500,000 Common shares for acquisition of intangible assets valued at $700,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">During the twelve months ended August 31, 2012 the Company issued
6,274,726  Common Shares valued at $23,868 pursuant to contractual obligations contained in certain convertible notes outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">During the twelve months ended August 31, 2012 the Company issued
75,000 shares of its Non Voting Convertible Preferred Stock for services rendered valued at $75,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On December 26, 2011 an employee
of the Company consented to the cancellation of 15,000 common shares previously issued as compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On December 29, 2011 75,000
common shares previously issued to the company&rsquo;s former Chief Financial Officer were returned for cancellation by the Company.
Of that amount 40,000 were subject to forfeiture and are cancelled pursuant to those forfeiture provisions at the company&rsquo;s
option and the company&rsquo;s former Chief Financial Officer has consented to cancellation of the remaining 35,000 common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">During the Quarter
ended May 31, 2012 a dividend of 3, 201,397 shares of Series B Preferred Stock was paid to the Company&rsquo;s common shareholders
of record as of February 21, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">On April 3, 2012 the Company issued 50,000,000
shares of common stock to David R. Koos, the Company&rsquo;s Chief Executive Officer, as a restricted stock award (&ldquo;Bonus
Shares&rdquo;).David Koos may not offer to sell, sell, transfer, pledge or otherwise dispose of the Bonus Shares prior to April
2, 2017 (&ldquo;Restricted Period&rdquo;). In the event that, prior to the expiration of the Restricted Period, David Koos voluntarily
ceases to be employed at the Company or is terminated for cause the Shares shall be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">On April 3, 2012 the Company issued 27,000,000
shares of common stock to seven employees as a restricted stock award (&ldquo;Bonus Shares&rdquo;).No employee may offer to sell,
sell, transfer, pledge or otherwise dispose of the Bonus Shares prior to April 2, 2017 (&ldquo;Restricted Period&rdquo;).In the
event that, prior to the expiration of the Restricted Period, any employee voluntarily ceases to be employed at the Company or
is terminated for cause his or her Shares shall be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">On April 3, 2012 the Company issued 15,000,000
shares of common stock to a consultant as a restricted stock award (&ldquo;Bonus Shares&rdquo;).The recipient may not offer to
sell, sell, transfer, pledge or otherwise dispose of the Shares prior to April 2, 2017 (&ldquo;Restricted Period&rdquo;). In the
event that, prior to the expiration of the Restricted Period, the recipient declines to provide if requested to provide, or is
unable to provide if requested to provide, consulting services to the Company of a nature that have been customarily provided by
the recipient to the Company the Shares shall be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On August 2, 2012 an employee of the Company consented to the cancelation
of 15,000,000 common shares issued to her as a Restricted Stock Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><B>NOTE 17. SUBSEQUENT EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Between September 4, 2012 and September 17, 2012 the Company sold
26,802,465 common shares to Southridge for the gross amount of $50,000 pursuant to the June Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On September 21 , 2012 the Company paid $20,000 of indebtedness
due to Southridge.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On September 20, 2012 the&nbsp;<FONT STYLE="background-color: white">Company
issued a convertible promissory note in the amount of $63,000 cash from which was received September 27, 2012. The note bears an
interest rate of eight percent (8%), matures on June 25, 2013. and may be converted after 180 days from execution of this note
for shares of the Company&rsquo;s common stock. The note may be converted at a thirty nine percent (39%) discount to the average
of the lowest 3 closing bid prices of the common stock during the 10 trading days prior to the conversion date. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On October 2 , 2012 the Company sold 10,837,849 common shares to
Southridge for the gross amount of $14,300 pursuant to the June Purchase Agreement. Total gross proceeds of $14,300 were utilized
to pay $14,300 of debt due to Southridge by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On October 17, 2012 the Company issued 23,000,000 common shares
in satisfaction of $19,320 of outstanding convertible indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On October 17, 2012 the Company amended its certificate of incorporation
in order to authorize 2,000,000,000 shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On October 22, 2012 the Company issued 10,810,811 common shares
in satisfaction of $8,000 of outstanding convertible indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">On
November 28, 2012 the &ldquo;Company executed an agreement (&ldquo;Agreement&rdquo;) with Gregory McDonald (&quot;McDonald&quot;),
Pet Pointers, Inc. (&quot;Pet Pointer&quot;) whereby Mc Donald and Pet Pointer would acquire from the Company all assets ( with
the exception of cash and accounts receivable) utilized by the Company in the operation of the McDonald Animal Hospital, a full
service veterinary clinic owned and operated by the Company and located in Santa Barbara, California (&ldquo;McDonald Asset Sale&rdquo;).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">On
October 10, 2012 a Complaint (&ldquo;Complaint&rdquo;) was filed in the Superior Court of the State of California against the
Company and David Koos by McDonald, a former employee of the Company, alleging breach of contract and breach of the covenant of
good faith and dealing in connection with the assumption of lease obligations by the Company in connection with the acquisition
of the assets of Pet Pointers, Inc breach of contract and breach of the covenant of good faith and dealing in connection with
an employment agreement enters into with McDonald inc connection with the Acquisition, breach of contract in connection with the
Acquisition purchase agreement, breach of the covenant of good faith and dealing in connection with the Acquisition purchase agreement,
implied indemnity in connection to amounts owed by McDonald to Anthony and Judi Marinelli, the Internal Revenue Service, and the
California Franchise Tax Board, intentional misrepresentation, negligent misrepresentation , failure to pay wages and violations
of Sections 2802, 203, and 2806 of the California Labor Code. The Complaint sought judgment for nominal damages, actual damages,
compensatory damages, lost wages, compensation, expenses wage benefits and penalties pursuant to California Labor Code Sections
203 et al, 2802 and 2806, indemnification, accrued interest, punitive damages, costs of suit and attorney&rsquo;s fees.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">As consideration to the Company for the assets
acquired, McDonald and Pet Pointers provided to the Company a General release whereby McDonald and Pet Pointer waive, release and
discharge the Company and their respective assignees, officers, directors, shareholders, boards, owners, employees, attorneys,
agents, trustors, trustees, beneficiaries, heirs, successors, and representatives from all known and unknown claims, demands, causes
of action, attorney's fees, costs, or expenses including:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">(1) All claims
relating to the Complaint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">(2) Those owed by
McDonald to Anthony and Judi Marinelli which the Company became obligated to pay on McDonald&rsquo;s behalf pursuant to the
asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011. The
balance due on this obligation as of December 5, 2012 was $55,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">(3) Those amounts
owed by McDonald to the Internal Revenue Service which the Company became obligated to pay on McDonald&rsquo;s behalf
pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on
January 4, 2011. The balance due on this obligation as of December 5, 2012 was $6,369.69.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">(4) Those amounts
owed by McDonald to the California Franchise Tax Board which the Company became obligated to pay on McDonald&rsquo;s behalf
pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on
January 4, 2011. The balance due on this obligation as of December 5, 2012 was $3,474.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; margin-bottom: 0pt"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; text-indent: 0.5in; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">Assets
disposed of pursuant to the Agreement include approximately $4,897 of Property Plant and Equipment net of accumulated depreciation
as well as all inventory held at the McDonald Animal Hospital.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">Assets
disposed of pursuant to the Agreement also include&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">(i)
Essentially all intellectual property, including computer software, utilized in connection with the operation of the McDonald
Animal Hospital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">(ii)
All telephone numbers, fax numbers, service marks, trademarks, trade names, fictitious business names, websites, business
email addresses, vendor lists, promotional materials, vendor records and any and all business records including, but not
limited to, such items stored in computer memories, microfiche, paper record or by any other means relevant to the operation
of the McDonald Animal Hospital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">(iii)
All customer lists, customer contacts, and any and all customer records that are related to the McDonald Animal Hospital.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">As
a result of the agreement, the Company anticipates recording a non-cash pre-tax charge for the impairment of goodwill recorded
in connection with the acquisition of the McDonald Animal Hospital of approximately $405,000 for the quarter ended November 30,
2012.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0; margin-bottom: 0pt; text-align: justify">Pursuant
to the Agreement, the Company is obligated to make payment of $13,000 within five days of the Closing of the Agreement as such
term is defined in the Agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Pursuant to the Agreement, the Company agrees to waive, release
and discharge McDonald and Pet Pointer from all known and unknown claims, demands, causes of action, attorney's fees, costs, or
expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Item 9. Changes in and Disagreements with Accountants
on Accounting and Financial Disclosure</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify"><BR>
(a) On September 27, 2012 the Board of Directors of . (the &ldquo;Registrant&rdquo; or the &ldquo;Company&rdquo;) approved of the
dismissal of John Kinross-Kennedy, CPA (&ldquo;Kennedy&rdquo;) as the Registrant&rsquo;s independent registered public accounting
firm.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">Kennedy&rsquo;s&nbsp;&nbsp;report
of the Company&rsquo;s financial statements for the fiscal years ended August 31, 2011 and&nbsp;&nbsp;August 31, 2010&nbsp;&nbsp;did
not contain any adverse opinion or disclaimer of opinion, nor was modified as to uncertainty, audit scope, or accounting principles.
The audit reports prepared by Kennedy for the fiscal years ending August 31, 2011 and August 31, 2010 contained a paragraph with
respect to the Company's ability to continue as a going concern.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">During the Registrant's two most
recent fiscal years and the subsequent interim periods thereto there were no disagreements with Kennedy, whether or not resolved,
on any matter of accounting&nbsp;principles or practices, financial statement disclosure, or auditing scope or procedure, which,
if not resolved to Kennedy&rsquo;s satisfaction, would have caused it to make reference to the subject matter of the disagreement
in connection with its report on the Registrant's financial statements.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">On September 27, 2012, the Board
of Directors of the Registrant, acting as the Registrant's Audit Committee, approved the engagement of Anton and Chia, LLP as its
independent auditor. On same date, September 27, 2012, the accounting firm of Anton and Chia, LLP was engaged as the Registrant's
new independent registered public accounting firm.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">(b) On December 4, 2012 the Board
of Directors of Entest BioMedical, Inc. (the &ldquo;Registrant&rdquo; or the &ldquo;Company&rdquo;) approved of the dismissal of
Anton and Chia, LLP (&ldquo;Anton&rdquo;) as the Registrant&rsquo;s independent registered public accounting firm.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">Since September 27, 2012 (the date
on which Anton has been engaged as the Registrant&rsquo;s independent registered public accounting firm) Anton has neither reviewed
nor completed an audit of any of the financial statements of the Registrant.&nbsp;&nbsp;Therefore, no reports of Anton&nbsp;&nbsp;on
the Registrant&rsquo;s financial statements for either of the past two years or subsequent interim period contained an adverse
opinion or disclaimer of opinion, or was qualified or modified as to uncertainty, audit scope or accounting principles as no such
reports have been prepared. The Company&nbsp;&nbsp;disagreed with the conclusion arrived at by Anton while performing audit procedures
for the year ended August 31, 2012 that&nbsp;&nbsp;&nbsp;&nbsp;the Company had not appropriately accounted for the conversion features
of&nbsp;&nbsp;convertible notes payable and that the Company had not appropriately accounted for certain&nbsp;&nbsp;equity transactions.&nbsp;&nbsp;The
accounting treatment for the conversion features of convertible notes payable was discussed&nbsp;&nbsp;&nbsp;by Anton and the sole
Director of the Company and the Company has authorized Anton to respond fully to the inquiries of the successor accountant concerning
the subject matter of all disagreements.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">On December 4, 2012, the Board of
Directors of the Registrant, acting as the Registrant's Audit Committee, approved the engagement of Seale and Beers, Certified
Public Accountants LLC (&ldquo;S&amp;B&rdquo;) as its independent auditor. On same date, December 4, 2012, the accounting firm
of S&amp;B was engaged as the Registrant's new independent registered public accounting firm.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Item 9A. Controls and Procedures</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">a) Evaluation of disclosure controls
and procedures.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">The principal executive officer
and principal financial officer have evaluated the Company&rsquo;s disclosure controls and procedures as of August 31, 2012. Based
on this evaluation, they have concluded that the disclosure controls and procedures were effective to ensure that the information
required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded,
processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules and forms and to ensure that
information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of
1934 is accumulated and communicated to the Company&rsquo;s management, including its principal executive and principal financial
officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. David
Koos is the Company&rsquo;s CEO and acting CFO. He&nbsp;&nbsp;functions&nbsp;&nbsp;as the Company&rsquo;s&nbsp;&nbsp;principal
executive officer and principal financial officer.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">b) Management&rsquo;s annual report
on internal control over financial reporting.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">Management of the Company is responsible
for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) promulgated under
the Securities and Exchange Act of 1934. Rule 13a-15(f) defines internal control over financial reporting as follows:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&ldquo;The term internal control
over financial reporting is defined as a process designed by, or under the supervision of, the issuer's principal executive and
principal financial officers, or persons performing similar functions, and effected by the issuer's board of directors, management
and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures
that:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">Pertain to the maintenance of records
that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the issuer;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">Provide reasonable assurance that
transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the issuer are being made only in accordance with authorizations of management
and directors of the issuer; and</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">Provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use or disposition of the issuer's assets that could have a material
effect on the financial statements.&rdquo;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">The Company&rsquo;s internal control
over financial reporting is a process designed under the supervision of the Company&rsquo;s management to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of the Company&rsquo;s financial statements for external purposes
in accordance with U.S. generally accepted accounting principles.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">In designing and evaluating our
disclosure controls and procedures, our management recognized that disclosure controls and procedures, no matter how well conceived
and operated, can provide only a reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures
are met.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify"><BR>
The Company&rsquo;s management assessed the effectiveness of its internal control over financial reporting as of August 31, 2010
based on the framework in &ldquo;Internal Control over Financial Reporting &ndash; Guidance for Smaller Public Companies (2006)
issued by the Committee of Sponsoring Organizations of the Treadway Commission.&rdquo;&nbsp;&nbsp;Based on its assessment, management
believes that, as of August 31, 2010, the Company&rsquo;s internal control over financial reporting is effective.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">Management's report was not subject
to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission
that permit the company to provide only management's report in this annual report. This exemption for smaller reporting companies
provided under the temporary rules referenced above has been made permanent under Section 989G of the Dodd-Frank Wall Street Reform
and Consumer Protection Act.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white; text-align: justify">(c) There have been no changes during
the quarter ended August 31, 2012 in the Company&rsquo;s internal controls over financial reporting that have materially affected,
or are reasonably likely to materially affect, internal control over financial reporting.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Item 10. Directors, Executive Officers and Corporate Governance</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On June 19, 2009 the Board of Directors of &nbsp;the Company elected
David R. Koos, 52, &nbsp;a director of the Company and appointed Dr. Koos President, Chief Executive Officer, Secretary, Chief
Financial Officer, Principal Accounting Officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Koos resigned as Chief Financial Officer on March 31, 2010
and assumed the position of Acting Chief Financial Officer and Principal Accounting Officer on August 8, 2011 upon the resignation
of Tammy L. Reynolds who served as Chief Financial Officer from the period from March 31, 2010 to August 8, 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Dr. Koos has served as Chairman, CEO, President, Secretary, and
Acting CFO of the BMSN since June 19, 2006, and as Chairman CEO, President, Secretary, and Acting CFO of Entest CA since August
22, 2008</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">education:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">DBA - Finance (December 2003)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Atlantic International University</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Ph.D. - Sociology (September 2003)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Atlantic International University</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">MA - Sociology (June 1983)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">University of California - Riverside, California</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Five Year Employment History:</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Position:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Company Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Dates:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman, President, CEO and Acting CFO</FONT></TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Bio-Matrix Scientific Group, Inc.*</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">June 14, 2006 (Chairman) to Present</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">June 19, 2006 (President, CEO and Acting CFO)</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">June 19, 2006 (Secretary) to Present</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman, CEO, Secretary &amp; Acting CFO</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;Frezer Inc.</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">May 2, 2005 to February 2007</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman, CEO &amp; Acting CFO</FONT></TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;BMXP Holdings, Inc.</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 6, 2004 to June 2008</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Managing Director &amp; President</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cell Source Research Inc.</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December 5, 2001 to Present</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Managing Director &amp; President</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Venture Bridge Inc.</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November 21, 2001 to Present</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman of the Board of Directors, CFO &amp; Secretary</FONT></TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Cell Bio-Systems Inc.</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">(New York)</P></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">July 17, 2003 to December 1, 2003</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registered Representative</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amerivet Securities Inc.**</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 31, 2004 to February 2008</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">* As of January 28,2012 Bio-Matrix Scientific Group Inc.
owned 10,000,000 common shares of the company</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">** Amerivet Securities Inc. has not been active during the
period as the Chief Executive Officer was on deployment in Iraq through the U.S. Army Reserves.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Code of Ethics</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">On November 11, 2009 we adopted a Code of Ethics pursuant
to Section 406 of the Sarbanes-Oxley Act of 2002</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Director Independence</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Audit Committee and Audit Committee Financial Expert</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The sole member of the Company&rsquo;s board of Directors
may not be considered independent as he is also its sole officer.&nbsp;The Company is not&nbsp;a &quot;listed company&quot; under
Securities and Exchange Commission (&ldquo;SEC&rdquo;) rules and is&nbsp;therefore not required to have an audit committee comprised
of independent directors. The Company does not currently have an audit committee, however, for certain purposes of the rules and
regulations of the SEC and in accordance with the Sarbanes-Oxley Act of 2002, the Company&rsquo;s&nbsp;&nbsp;Board of Directors
is deemed to be its&nbsp;&nbsp;audit committee and as such functions as an audit committee and performs some of the same functions
as an audit committee including: (1) selection and oversight of our independent accountant; (2) establishing procedures for the
receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters; and (3) engaging outside
advisors. The Board of Directors has determined that its member is&nbsp;&nbsp;able to read and understand fundamental financial
statements and has substantial business experience that results in that member's financial sophistication. Accordingly, the Board
of Directors believes that&nbsp;its member has&nbsp;&nbsp;the sufficient knowledge and experience necessary to fulfill the duties
and obligations that an audit committee would have.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Nominating and Compensation Committees</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Company does&nbsp;not have standing nominating or compensation
committees, or committees performing similar functions. The&nbsp;board of directors believes that it is not necessary to have a
compensation committee at this time because the functions of such committee are adequately performed by the board of directors.
The board of directors also is of the view that it is appropriate for the Company not to have a standing nominating committee because
the board of directors has performed and will perform adequately the functions of a nominating committee. The Company is not&nbsp;a
&quot;listed company&quot; under SEC rules and is&nbsp;therefore not required to have a compensation committee or a nominating
committee.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Shareholder Communications</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">There has not been any defined policy or procedure requirements
for stockholders to submit recommendations or nomination for directors. There are no specific, minimum qualifications that the
board of directors believes must be met by a candidate recommended by the board of directors. Currently, the entire board of directors
decides on nominees, on the recommendation of any member of the board of directors followed by the board&rsquo;s review of the
candidates&rsquo; resumes and interview of candidates. Based on the information gathered, the board of directors then makes a decision
on whether to recommend the candidates as nominees for director. The Company does not pay any fee to any third party or parties
to identify or evaluate or assist in identifying or evaluating potential nominee.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Because&nbsp;management and the Board of Directors&nbsp;&nbsp;of
the Company&nbsp;are the same people, the Board of Directors has determined not to adopt a formal methodology for communications
from shareholders on the belief that any communication would be brought to the Board of Directors&rsquo; attention by virtue of
the co-extensive capacities of the Board of Directors.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Executive Compensation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white"><B>SUMMARY COMPENSATION
TABLE</B></FONT></P>

<P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 9pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">Name and Principal Position</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">Year</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Salary</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">($)</P></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Bonus</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">($)</P></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Stock</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Awards</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">($)</P></TD>
    <TD STYLE="text-align: center; border-bottom: black 1.5pt solid; vertical-align: bottom">
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Restricted</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Stock Awards</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">($)</P></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Option</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Awards</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">($)</P></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Non Equity</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Incentive</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Plan</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Compensation</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">($)</P></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Nonqualified</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Deferred</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Compensation</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Earnings</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">($)</P></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">All</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Other</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Compensation</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">($)</P></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Total</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">($)</P></TD></TR>
<TR>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">David Koos</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Chairman, President and CEO</P></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;From September 1, 2011 to &nbsp;August 31, 2012</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">$120,000*</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">400,000*****</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">$520,000</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">David Koos</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Chairman, President and CEO</P></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;From September 1, 2010 to &nbsp;August 31, 2011</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">$208,000****</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">$2,000**</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">$210,558</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Tammy Reynolds,</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;Former CFO and &nbsp;Director</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">(resigned from all positions</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">with &nbsp;the Company</P>
        <P STYLE="font: 9pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">effective August &nbsp;8,2011</P></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;From September1, 2010 to August 31, 2011</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">$65,961</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">$47,000</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">$50,000***</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">$162,961</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><B>* </B>Includes $102,000 <FONT STYLE="color: black; background-color: white">in
salary earned by David Koos which was accrued but unpaid for the fiscal year ended August 31, 2011</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><B>*****</B><FONT STYLE="color: black"> On&nbsp; April 3, 2012 the
Company issued 50,000,000 shares of common stock to David R. Koos as a restricted stock award (&ldquo;Bonus Shares&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">David Koos may not offer to sell, sell, transfer, pledge or otherwise
dispose of the Bonus Shares prior to April 2, 2017 (&ldquo;Restricted Period&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">In the event that, prior to the expiration of the Restricted Period,
David Koos voluntarily ceases to be employed at the Company or&nbsp; is&nbsp; terminated for cause the Shares shall be forfeited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">** represents 5,000 shares
of the Company&rsquo;s Series AA Preferred Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">**** Includes 190,558 in salary
earned by David Koos which was accrued but unpaid for the fiscal year ended August 31, 2011</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">***The Company and Ms. Reynolds
had agreed that Ms. Reynolds shall receive:</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 39px; font: 9pt/115% Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 19px; font: 9pt/115% Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">Compensation of $70,000 per annum for her services as Chief Financial Officer.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="font: 9pt/115% Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 9pt Times New Roman, Times, Serif">Fifty Thousand Dollars worth of the Common Shares of the Company (&ldquo;Compensation Shares&rdquo;) to be granted to Ms. Reynolds upon the completion of twelve months employment as CFO of the Company under the condition that80% of the Compensation Shares (&ldquo;Restricted Comp Shares&rdquo;) may not be sold, transferred, assigned, pledged or otherwise encumbered or disposed of by Ms. Reynolds (&ldquo;Transfer Restriction&rdquo;) except as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Upon the expiration
of one year from the date of the grant of the Compensation Shares, Transfer Restrictions shall no longer apply to 25% of the Restricted
Comp Shares.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Upon the expiration
of two years from the date of the grant of the Compensation Shares, Transfer Restrictions shall no longer apply to an additional
25% of the Restricted Comp Shares.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Upon the expiration
of three years from the date of the grant of the Compensation Shares, Transfer Restrictions shall no longer apply to an additional
25% of the Restricted Comp Shares</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Upon the expiration
of four years from the date of the grant of the Compensation Shares, Transfer Restrictions shall no longer apply to an additional
25% of the Restricted Comp Shares.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">As Ms. Reynolds is
no longer employed as CFO of the Company, any Restricted Comp Shares still subject to Transfer Restrictions shall be forfeited
by the Ms. Reynolds, and ownership of the Restricted Comp Shares shall be transferred back to the Company. &nbsp;As such, 80% of
the restricted Stock Award paid to Ms Reynolds during the fiscal year ended August 31, 2011 is subject to forfeiture. Ms. Reynolds
is currently not party to a written employment agreement with the Company.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">On December 29, 2011
75,000 common shares previously issued to Ms. Reynolds &nbsp;were returned for cancellation by the Company. Of that amount 40,000
were &nbsp;subject to forfeiture and were cancelled pursuant to those forfeiture provisions at the company&rsquo;s option and Ms.
Reynolds has consented to cancellation of the remaining 35,000 common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Item 12. Security Ownership of Certain Beneficial Owners
and Management and Related Stockholder Matters</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The following table sets forth information known to the Company
with respect to the beneficial ownership of each class of the Company&rsquo;s capital stock as of January 28, 2013 for (1)&nbsp;each
person known by the Company to beneficially own more than 5% of each class of the Company&rsquo;s voting securities, (2)&nbsp;each
executive officer, (3)&nbsp;each of the Company&rsquo;s directors and (4)&nbsp;all of the Company&rsquo;s executive officers and
directors as a group. As of November 1, 2011 the Company had 20,890, 501&nbsp;&nbsp;common shares outstanding and 5,000 Series
AA Preferred Shares outstanding</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font-size: 8pt">&nbsp;</FONT><FONT STYLE="font-size: 10pt; color: black; background-color: white">Based
on&nbsp;446,539,900 <FONT STYLE="background-color: white">shares issued and outstanding as of&nbsp;August 9, 2012 (Except
as otherwise indicated)</FONT>&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 2.25pt solid; font: 10pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title of Class</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt solid; font: 10pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name and Address of Beneficial Owner</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Amount and Nature</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;of Beneficial Owner</P></TD>
    <TD STYLE="border-bottom: black 2.25pt solid; font: 10pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Percent of Class</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common</FONT></TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">David R. Koos*</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">C/o Entest Bio Medical Inc., Inc</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">4700 SPRING STREET, SUITE 203, LA MESA, CALIFORNIA, 91942</P></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">60,000,000</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13.4%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All Officers and Directors As a Group</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">60,000,000</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13.4%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">*Includes 10,000,000
common shares owned by Bio-Matrix Scientific Group, Inc. (David Koos is CEO, President and Chairman of Bio-Matrix Scientific Group,
Inc.).</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">Based on 3,201,397 shares issued and outstanding as of&nbsp;
January 28, 2012</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 2.25pt solid; font: 10pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title of Class</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt solid; font: 10pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name and Address of Beneficial Owner</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Amount and Nature</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;of Beneficial Owner</P></TD>
    <TD STYLE="border-bottom: black 2.25pt solid; font: 10pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Percent of Class</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Series B Preferred</FONT></TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">David R. Koos*</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">C/o Entest Bio Medical Inc., Inc</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">4700 SPRING STREET, SUITE 203, LA MESA, CALIFORNIA, 91942</P></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1250000</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">39%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Series B Preferred</FONT></TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">National Financial Services, LLC</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">200 Liberty Street</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">New York NY 10281</P></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">201,585</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.2%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Series B Preferred</FONT></TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Sleezer family Trust</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">c/o Charles Sleezer</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">12550 Carson Street</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Hawaiian Gardens, CA</P></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">687,500</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">21.4%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Series B Preferred</FONT></TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Ronald J. Titterington and Kathy Snell</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">3880 W 11th Street</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Eugene Oregon</P></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">312,500</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9.7%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Series B Preferred</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All Officers and Directors as a Group*</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1250000</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">39%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">*Includes 1,250,000 Series B Preferred &nbsp;shares
owned by Bio-Matrix Scientific Group, Inc. (David Koos is CEO, President and Chairman of Bio-Matrix Scientific Group, Inc.).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Based on 5,000 shares
issued and outstanding as of</FONT>&nbsp; January 28<FONT STYLE="background-color: white">, 2012</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 2.25pt solid; font: 10pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title of Class</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt solid; font: 10pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name and Address of Beneficial Owner</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Amount and Nature</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;of Beneficial Owner</P></TD>
    <TD STYLE="border-bottom: black 2.25pt solid; font: 10pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Percent of Class</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Series AA Preferred Shares</FONT></TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">David R. Koos</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">C/o Entest Bio Medical Inc., Inc</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">4700 SPRING STREET, SUITE 203, LA MESA, CALIFORNIA, 91942</P></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5,000</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">100%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Series AA Preferred Shares</FONT></TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">All Officers and Directors</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">As a Group</P></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5,000</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">100%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">Based on 75,000 shares
issued and outstanding as of</FONT>&nbsp;January 28, 2012</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 2.25pt solid; font: 10pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title of Class</FONT></TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 2.25pt solid; font: 10pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name and Address of Beneficial Owner</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 2.25pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">Amount and Nature</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;of Beneficial Owner</P></TD>
    <TD STYLE="border-bottom: black 2.25pt solid; font: 10pt/115% Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Percent of Class</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NonVoting Convertible Preferred Shares</FONT></TD>
    <TD COLSPAN="3">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;Southridge Partners II LLP(1)</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">90 Grove Street</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">Ridgefield CT</P></TD>
    <TD COLSPAN="2" STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">75,000</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">100%</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">All Officers and Directors</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">As a Group</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>
        <P STYLE="font: 11pt/normal Calibri, Helvetica, Sans-Serif; margin: 0 0 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)
        &nbsp;Stephen Hicks possesses voting power and investment power over 75,000</FONT>&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">NonVoting
        Convertible Preferred Shares held by Southridge.</FONT></P></TD>
    <TD COLSPAN="2" STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD>
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0%</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Item 13. Certain Relationships and Related Transactions,
and Director Independence</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0pt; text-align: justify">During the quarter ended November 30, 2011 David
Koos made loans to the Company totaling $8,400. These loans are due and payable at the demand of David&nbsp; Koos and bear simple
interest at a rate of 15% per annum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">During the quarter ended February 29, 2012 David Koos made loans
to the Company totaling $7,550. These loans are due and payable at the demand of David&nbsp; Koos and bear simple interest at a
rate of 15% per annum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">During the quarter ended February 29, 2012 David Koos granted to
the Sherman Family Trust, an irrevocable trust for the benefit of Blossom Sherman, all rights to and interest in $25,956 in unpaid
indebtedness owed by the Company (bearing simple interest at a rate of 15% per annum and due and payable at the demand of the holder)
as well as $3,051 in unpaid interest owed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">During the quarter ended May 31, 2012 David Koos made loans to the
Company in the amount of&nbsp; $13,625. These loans are due and payable at the demand of David&nbsp; Koos and bear simple interest
at a rate of 15% per annum</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="background-color: white">As of August 31, 2012 the
Company remains indebted to David R. Koos in the principal amount of $30,180 </FONT>due and payable at the demand of David&nbsp;
Koos and bearing simple interest at a rate of 15% per annum</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">As of August 31 , 2012 Bio-Matrix Scientific Group, Inc.
(&ldquo;BMSN&rdquo;) , a major shareholder of the Company, is indebted to the Company in the amount of $39,140. This amount is
non interest bearing and is due at the demand of the Company.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Director Independence</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Audit Committee and Audit Committee Financial Expert</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Company&rsquo;s&nbsp; sole director may not be considered
independent as&nbsp;&nbsp;he is also an&nbsp;&nbsp;officer.&nbsp;The Company is not&nbsp;a &quot;listed company&quot; under Securities
and Exchange Commission (&ldquo;SEC&rdquo;) rules and is&nbsp;therefore not required to have an audit committee comprised of independent
directors. The Company does not currently have an audit committee, however, for certain purposes of the rules and regulations of
the SEC and in accordance with the Sarbanes-Oxley Act of 2002, the Company&rsquo;s&nbsp;&nbsp;Board of Directors is deemed to be
its&nbsp;&nbsp;audit committee and as such functions as an audit committee and performs some of the same functions as an audit
committee including: (1) selection and oversight of our independent accountant; (2) establishing procedures for the receipt, retention
and treatment of complaints regarding accounting, internal controls and auditing matters; and (3) engaging outside advisors. The
Board of Directors has determined that its sole member is able to read and understand fundamental financial statements and has
substantial business experience that results in the member's financial sophistication. Accordingly, the Board of Directors believes
that&nbsp;its member has the sufficient knowledge and experience necessary to fulfill the duties and obligations that an audit
committee would have.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Nominating and Compensation Committees</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Company does&nbsp;not have standing nominating or compensation
committees, or committees performing similar functions. The&nbsp;Board of Directors believes that it is not necessary to have a
compensation committee at this time because the functions of such committee are adequately performed by the board of directors.
The Board of Directors also is of the view that it is appropriate for the Company not to have a standing nominating committee because
the Board of Directors has performed and will perform adequately the functions of a nominating committee. The Company is not&nbsp;a
&quot;listed company&quot; under SEC rules and is&nbsp;therefore not required to have a compensation committee or a nominating
committee.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Shareholder Communications</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">There has not been any defined policy or procedure requirements
for stockholders to submit recommendations or nomination for directors. There are no specific, minimum qualifications that the
board of directors believes must be met by a candidate recommended by the board of directors. Currently, the entire board of directors
decides on nominees, on the recommendation of any member of the board of directors followed by the board&rsquo;s review of the
candidates&rsquo; resumes and interview of candidates. Based on the information gathered, the board of directors then makes a decision
on whether to recommend the candidates as nominees for director. The Company does not pay any fee to any third party or parties
to identify or evaluate or assist in identifying or evaluating potential nominee.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Board of Directors has determined not to adopt a formal
methodology for communications from shareholders on the belief that any communication would be brought to the board of directors&rsquo;
attention by virtue of communication with management</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><B>Item 14. Principal Accounting Fees and Services</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The following table sets forth the aggregate fees billed
to us by John Kinross-Kennedy, CPA during the period beginning September 1, 2010 and ending August 31, 2011:</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; width: 88%; padding-right: 1.6pt; font: 11pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Audit Fees</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt; font: 11pt/115% Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 1.6pt; font: 11pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="vertical-align: top; width: 9%; padding-right: 1.6pt; font: 11pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4,600</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt; font: 11pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Audit Related Fees</FONT></TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">400</FONT></TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tax Fees</FONT></TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;0</FONT></TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All Other Fees</FONT></TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,800</FONT></TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 3px double; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 3px double; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7,800</FONT></TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><I>Audit Fees:</I> Aggregate fees billed for professional
services rendered for the audit of the Company's annual financial statements.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><I>Audit Related Fees:</I> &nbsp; Aggregate fees billed for
professional services rendered for assurance and related services that were reasonably related to the performance of the audit
or review of our financial statements and are not reported under &ldquo;Audit Fees&rdquo; above. In 2010 these fees were primarily
derived from review of financial statements in the Company's Form&nbsp;10Q Reports.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><I>All Other Fees:</I> Audit of the financial statements
of Pet Pointers, Inc.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The following table sets forth the aggregate fees billed
to us by John Kinross-Kennedy, CPA during the period beginning September 1, 2011 and ending August 31, 2012:</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; width: 88%; padding-right: 1.6pt; font: 11pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Audit Fees</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt; font: 11pt/115% Times New Roman, Times, Serif; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 1.6pt; font: 11pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="vertical-align: top; width: 9%; padding-right: 1.6pt; font: 11pt/115% Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4,000</FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; padding-right: 0.8pt; font: 11pt/115% Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Audit Related Fees</FONT></TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,300</FONT></TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tax Fees</FONT></TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;0</FONT></TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom; font: 12pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 1pt solid; font: 12pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: right">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 3pt double; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: Black 3pt double; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5,300</FONT></TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><I>Audit Fees:</I> Aggregate fees billed for professional
services rendered for the audit of the Company's annual financial statements.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><I>Audit Related Fees:</I> &nbsp; Aggregate fees billed for
professional services rendered for assurance and related services that were reasonably related to the performance of the audit
or review of our financial statements and are not reported under &ldquo;Audit Fees&rdquo; above. In 2012 these fees were primarily
derived from review of financial statements in the Company's Form&nbsp;10Q Reports.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">All services listed were pre-approved by the Board of Directors,
functioning as the Audit Committee in accordance with Section 2(a) 3 of the Sarbanes-Oxley Act of 2002.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">The Board has considered whether the services described above
are compatible with maintaining the independent accountant's independence and has determined that such services have not adversely
affected the independence John Kinross-Kennedy.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;<BR></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><B>Item 15. Exhibit Index</B></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">EXHIBIT INDEX</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="font-weight: bold; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit No.</B></FONT></TD>
    <TD><B>Description</B></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3(i)(a)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Articles of Incorporation</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3(ii)(b)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bylaws</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1 ( c)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Agreement by and Between David Koos and the Company</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2 (Incorporated by Reference to Exhibit 10.2 of the Company&rsquo;s Form S-1 filed June 12, 2012)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Terms of Employment Agreement by and between the Company and Tammy Reynolds</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3 (d)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">August 2010 Agreement by and between the Company and TheraCyte, Inc.</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3 (e)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Asset Purchase Agreement by and between the Company, Dr. Gregory McDonald and Pet Pointers</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.4 (f)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit A to Asset Purchase Agreement by and between the Company, Dr. Gregory McDonald and Pet Pointers</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5 (g)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit B to Asset Purchase Agreement by and between the Company, Dr. Gregory McDonald and Pet Pointers</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.6 (h)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CRO Agreement by and between the Company and RenovoCyte LLC</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3(i)(2)(i)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Designations Series AA Preferred Stock</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.7(j)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8% ASHER NOTE $42,500</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.8(k)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8% ASHER NOTE $37,500</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.9(l)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8% ASHER NOTE $35,000</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.10(m)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8% ASHER NOTE $32,500</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3(i)(3) (n)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment to Certificate of Incorporation dated June 4, 2009</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3(ii)(2) (o)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bylaws of Entest BioMedical, inc., a California corporation and wholly owned subsidiary of the Registrant</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3(i)(4) (p)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Incorporation of Entest BioMedical, inc., a California corporation and wholly owned subsidiary of the Registrant</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.11(q)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8% ASHER NOTE $37,500</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3(i)(5) ( r)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Designations Series B &nbsp;Preferred Stock</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3(i) (6)(s)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment to Certificate of Incorporation</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.12 (t)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Equity purchase Agreement, Southridge Feb 27, 2012</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.13(u)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registration Rights Agreement, Southridge</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.14(Incorporated by Reference to Exhibit 10.14 of the Company&rsquo;s Form S-1 filed June 12, 2012)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Line of Credit Promissory Note December 1, 2010 Bio Technology Partners Business Trust</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.15(Incorporated by Reference to Exhibit 10.15 of the Company&rsquo;s Form S-1 filed June 12, 2012)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Line of Credit Promissory Note December 1, 2010 &nbsp;Venture Bridge Advisors, Inc.</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.16(Incorporated by Reference to Exhibit 10.16 of the Company&rsquo;s Form S-1 filed June 12, 2012)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Line of Credit Promissory Note December 1, 2010 &nbsp;Bombardier Pacific ventures</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.17(Incorporated by Reference to Exhibit 10.17 of the Company&rsquo;s Form S-1 filed June 12, 2012)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Line of Credit Promissory Note December 1, 2010 &nbsp;David Koos</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3(i)(7) (v)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment to Certificate of Incorporation</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.18(Incorporated by Reference to Exhibit 10.18 of the Company&rsquo;s Form S-1 filed June 12, 2012)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Agreement amending terms of outstanding Debt by the Company</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.19(Incorporated by Reference to Exhibit 10.19 of the Company&rsquo;s Form S-1 filed June 12, 2012)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Agreement amending terms of outstanding Debt by the Company</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.20(Incorporated by Reference to Exhibit 10.20 of the Company&rsquo;s Form S-1 filed June 12, 2012)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Agreement amending terms of outstanding Debt by the Company</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.21(w)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Bonus Share Agreement</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.1</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Opinion Regarding Legality</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14 (y)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Code of Ethics</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.24 (aaaa)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Assignment dated June 15, 2009 by and between Entest BioMedical, Inc. and &nbsp;Bio-Matrix Scientific Group, Inc.</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.22 (z)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lease</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3(i)(8) (aa)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Text of Amendment to Certificate of Incorporation</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.23(aaa)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8% ASHER NOTE $42,500</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.24 (aaaa)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Assignment dated June 15, 2009 by and between Entest BioMedical, Inc. and &nbsp;Bio-Matrix Scientific Group, Inc.</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.25(Incorporated by Reference to Exhibit 10.25 of the Company&rsquo;s Form S-1 filed June 12, 2012)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Advisory Board Letter Agreement</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.26 (aaaaa)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Equity Purchase Agreement Southridge June 1 2012</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.27(Incorporated by Reference to Exhibit 10.27 of the Company&rsquo;s Form S-1 filed June 12, 2012)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Amendment to Registration Rights Agreement</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.28(Incorporated by Reference to Exhibit 10.28 of the Company&rsquo;s Form S-1 filed June 12, 2012)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Termination Letter February 27 Equity Purchase Agreement</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
        <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="font-weight: bold; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="font-weight: bold; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Description</B></FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.29(zzzzzzzz1)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AGREEMENT AMENDING TERMS OF OUTSTANDING DEBT BY THE COMPANY</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.30(zzzzzzzz2)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AGREEMENT AMENDING TERMS OF OUTSTANDING DEBT BY THE COMPANY</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.31(zzzzzzzz3)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AGREEMENT AMENDING TERMS OF OUTSTANDING DEBT BY THE COMPANY</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.32(zzzzzzzz4)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AGREEMENT AMENDING TERMS OF OUTSTANDING DEBT BY THE COMPANY</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.33(zzzzzzzz5)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AGREEMENT AMENDING TERMS OF OUTSTANDING DEBT BY THE COMPANY</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.34(zzzzzzzz6)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">AGREEMENT AMENDING TERMS OF OUTSTANDING DEBT BY THE COMPANY</FONT></TD>
    </TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">10.35 ( incorporated by Reference to Exhibit 10.35 of the
        company&rsquo;s amended Form S-1</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Filed August 17,2012)</P></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ASHER NOTE $63,000</FONT></TD>
    </TR>
<TR STYLE="background-color: White">
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">10.36( incorporated by Reference to Exhibit 10.36 of the
        company&rsquo;s amended Form S-1</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Filed August 17,2012)</P></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">TERMS OF COMPENSATION DAVID KOOS</FONT></TD>
    </TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>




<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: middle; width: 45%">10.38 (incorporated by reference to Exhibit 10.1 Of the Company&rsquo;s 8-K filed December 12, 2012 ) &nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: middle; width: 55%">Settlement Agreement with G. McDonald</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: middle">3.i (8) (Incorporated by Reference to Exhibit 3 (i) of the Company&rsquo;s 8-K filed October 19, 2012</TD>
    <TD STYLE="text-align: left; vertical-align: middle">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: middle">10.39</TD>
    <TD STYLE="text-align: left; vertical-align: middle">Line of Credit Promissory Note Sherman family Trust</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: middle">31.1</TD>
    <TD STYLE="text-align: left; vertical-align: middle">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: middle">31.2</TD>
    <TD STYLE="text-align: left; vertical-align: middle">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; vertical-align: middle">32.1</TD>
    <TD STYLE="text-align: left; vertical-align: middle">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 &nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: middle">32.2</TD>
    <TD STYLE="text-align: left; vertical-align: middle">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 &nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 42px; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 3(1) of the Company's Form S-1 Filed &nbsp;November 4, 2008</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 3(2) of the Company's Form S-1 Filed &nbsp;November 4, 2008</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10(1) of the Company's Form10-K &nbsp;Filed &nbsp;November 17, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10(1) of the Company's Form10-K &nbsp;Filed &nbsp;November 16, 2010</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(e)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10(1) of the Company's Form 8-K Filed December 17, 2010</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(f)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10(2) of the Company's Form 8-K Filed December 17, 2010</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(g)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10(3) of the Company's Form 8-K Filed December 17, 2010</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(h)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10(3) of the Company's Form 8-K Filed October 24, 2011</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 3(i) of the Company's Form 8-K Filed June 10, 2011</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(j)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10(9) of the Company's Form 10-K &nbsp;filed November 3 2011</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(k)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10(10) of the Company's Form 10-K &nbsp;filed November 3 2011</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(l)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10(11) of the Company's Form 10-K &nbsp;filed November 3 2011</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(m)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10(12) of the Company's Form 10-K &nbsp;filed November 3 2011</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(n)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 3(i) (2)of the Company's Form 8-K Filed June 10, 2011</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(o)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 3(ii) of the Company's Form 8-K Filed June 10, 2011</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(p)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 3(i) of the Company's Form 8-K Filed June 10, 2011</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(q)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10.1 of the Company's Form 10-Q Filed January 11, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">( r)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 3(i) of the Company's Form 8-K Filed February 9, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(s)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit (3)(i) of the Company's Form 10-Q Filed February 9, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(t)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10.1 of the Company's Form 10-Q Filed February 9, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(u)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10.2 of the Company's Form 10-Q Filed February 9, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(v)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 3(i) of the Company's Form 8-K Filed March 22, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(w)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10.1 of the Company's Form 8-K Filed April 5, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(x)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed as Exhibit 5.1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(y)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 14 of the Company's Form10-K &nbsp;Filed &nbsp;November 17, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(z)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10.1 of the Company's Form 10-Q Filed March 28, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(aa)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 3(i) of the Company's Form 8-K Filed April 25, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(aaa)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10 of the Company's Form 8-K Filed April 25, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(aaaa)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10.2 of the Company's Form 8-K Filed July 10, 2009</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(aaaaa)</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Incorporated by Reference to Exhibit 10.1 of the Company's Form 8-K Filed June 4, 2012</FONT></TD></TR>
</TABLE>


<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(zzzzzzzz1) Incorporated by Reference to Exhibit 10.1 of the Company's Form 10-Q Filed July 23, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(zzzzzzzz2) Incorporated by Reference to Exhibit 10.2 of the Company's Form 10-Q Filed July 23, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(zzzzzzzz3) Incorporated by Reference to Exhibit 10.3 of the Company's Form 10-Q Filed July 23, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(zzzzzzzz4) Incorporated by Reference to Exhibit 10.4 of the Company's Form 10-Q Filed July 23, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(zzzzzzzz5) Incorporated by Reference to Exhibit 10.5 of the Company's Form 10-Q Filed July 23, 2012</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt/115% Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(zzzzzzzz6) Incorporated by Reference to Exhibit 10.6 of the Company's Form 10-Q Filed July 23, 2012</FONT></TD></TR>
</TABLE>


<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->
<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in; text-align: justify">Pursuant to the requirements of Section&nbsp;13
or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 38%; padding-right: 0.8pt; font: 11pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 11%; padding-right: 0.8pt; font: 11pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 0.8pt; font: 11pt/115% Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 47%; padding-right: 1.6pt; font: bold 11pt/115% Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Entest BioMedical, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    David R. Koos</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: David R. Koos</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 1.6pt 0pt 0; text-align: justify">Title: President,
Chairman, Chief Executive Officer</P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: </FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-indent: 0.5in; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities
indicated on February 1, 2013.</P>

<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 38%; padding-right: 0.8pt; font: 11pt/115% Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 11%; padding-right: 0.8pt; font: 11pt/115% Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 4%; padding-right: 1.6pt; font: 11pt/115% Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="vertical-align: top; width: 47%; padding-right: 1.6pt; font: 11pt/115% Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    David R. Koos</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: David R. Koos</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: President, Chairman of the Board of Directors, Chief Executive Officer, Acting Chief Financial Officer</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 0.8pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 11pt/115% Times New Roman, Times, Serif; padding-right: 1.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: </FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt/normal Times New Roman, Times, Serif; margin: 0 0 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
